



Royal Brisbane and Women's Hospital

# RBWH Research Report 2024

Cancer Care Services

Metro North  
Health



Queensland  
Government



Metro North Health acknowledges the Traditional Custodians of the Land upon which we live, work and walk, and pay our respects to Elders both past and present.

Published by the State of Queensland (Metro North Hospital and Health Service), 2025

This document is licensed under a Creative Commons Attribution 3.0 Australia licence. To view a copy of this licence, visit [creativecommons.org/licenses/by/3.0/au](https://creativecommons.org/licenses/by/3.0/au)

© State of Queensland (Metro North Hospital and Health Service) 2025

You are free to copy, communicate and adapt the work, as long as you attribute the State of Queensland (Metro North Hospital and Health Service).

For more information, contact:

RBWH Research Services, Metro North Hospital and Health Service, Block 7, Level 8, Herston QLD 4006  
email [RBWH\\_Research\\_ESO@health.qld.gov.au](mailto:RBWH_Research_ESO@health.qld.gov.au)

An electronic version of this document is available at <https://metronorth.health.qld.gov.au/rbwh/research>.

Disclaimer:

The content presented in this publication is distributed by the Queensland Government as an information source only. The State of Queensland makes no statements, representations or warranties about the accuracy, completeness or reliability of any information contained in this publication. The State of Queensland disclaims all responsibility and all liability (including without limitation for liability in negligence) for all expenses, losses, damages and costs you might incur as a result of the information being inaccurate or incomplete in any way, and for any reason reliance was placed on such information.

# Contents

Cancer Care Services ..... 2

Haematology & BMT ..... 3

Radiation Oncology ..... 15

Medical Oncology..... 23

Cancer Care Nursing Research ..... 39

Allied Health Professions ..... 43

## Cancer Care Services



**Associate Professor Melissa Eastgate**  
**A/Executive Director**  
**Cancer Care Services**

Cancer Care Services (CCS) at RBWH continues to go from strength to strength. Our committed multidisciplinary team continues to lead the development of research that improves the lives of our patients every day across their whole Cancer Care Journey.

The grants awarded this year showcase the work being done across our service, with our haematology team being successful in being awarded grants across a number of programs including the Australian Cancer Research Foundation, NHMRC ideas grants and a MNHHS Clinician Research Fellowship.

The appointment of Professor Kim Alexander as the Professor of Nursing, a joint appointment between the Queensland University of Technology and RBWH has been a welcome addition to our team. She has been integral in developing our Nursing Research Action Plan, with the team being awarded 2 grants last year.

The radiation team were successful in being awarded grants including an MRFF grant for older Australians with cancer, Robyn Cheuk, Scott Crowe, and Rachael Wilks, as well as staff from STARS and the Comprehensive Breast Cancer Institute, won the Transforming Health Award at the 2024 Queensland Health Awards for Excellence, for their Breast Cancer Intraoperative Radiation Therapy (IORT) service.

The medical oncology team runs a very large trials unit and has been particularly successful with developing their collaboration with the nuclear medicine team to run theranostics trials in a number of tumour types. They also continue to be involved with many of our national trials groups helping develop and lead new studies such as the STOPNET study.

Our allied health colleagues are integral members of the CCS team, with many collaborations occurring across the service. They have also won several awards including at the Dietitians Australia National Conference and the RBWH QuaRRIES.

On behalf of the CCS executive team, thank you to all of our staff who support this important research, which our patients benefit from every day.



## Haematology & BMT



**Dr Cameron Curley**

**Director Clinical Haematology & BMT**

The Department of Haematology and BMT provides exceptional care for patients with blood disorders and cancers through a comprehensive research framework driving clinical research through translational, correlative, collaborative and investigator initiated clinical trials in common and rare blood cancers. Ongoing research highlights continued through 2024 with the expansion of clinical trials in the areas of CAR T cell therapy for a range of blood cancers, novel approaches to the prevention of graft versus host disease post allogeneic stem cell transplantation, integration of immunotherapy into myeloma therapy, the use of novel mutation specific targeted therapies in Myeloproliferative Neoplasms and the practice changing contributions the field of gene therapy in Haemophilia.

A number of notable grants were attained in 2024 including:

Australian Cancer Research Foundation ACRF grant – 2023-2028 (\$2 million)

NHMRC Ideas Grant (CI-D) – 2024-2027 (\$1.7 million)

MNHHS Clinician Research Fellowship – 2024-2027 (\$285k)

QCOG Cancer Clinical Trial Data Manager Grant (\$64k)

We are grateful for the continued efforts of the whole Haematology and BMT research team for their contributions in 2024 to expand and drive innovative research for our patients. We would like to congratulate Dr Sally Campbell on the completion of her PhD in the area of inherited and acquired bleeding disorders and her appointment as the AHDCO Clinical research Consultant 2024-2026. We would also like to commend Robyn Western and Renee Campbell for being awarded the Best Nurses Poster Award at BLOOD24 annual conference.



**Dr Jane Mason**  
**Director of Queensland Haemophilia Centre**

2024 was another exciting year for the Queensland Haemophilia Centre (QHC) working in collaboration with the Clinical Research Unit Cancer Care Services and the Cellular Therapy/ BMT Laboratory. In the Von Willebrand space, the QHC has joined an international study exploring treatment options for severe von Willebrand disease, which included recruitment of phase I patients. We will continue onto phase 2/3 for this same product. At the national Blood Conference this year I was part of the organising committee; Dr Campbell updated our national colleagues on novel therapies in the bleeding disorders space. We are also commencing a phase I gene therapy trial in Haemophilia B using CRISPR/Cas9 in addition to AAV vector technology.




**QLD Haemophilia Team Royal Brisbane and Women's Hospital**

Left to right: Tracey Gilbert, Natalie Karlovic, Alex Klever, Michelle Allan, Lara Nicholson, Dr Sally Campbell, Beryl Zeissink, Linda Mason, Dr Jane Mason

Successful Research Higher Degree candidates in 2024

Name	Title	Month Competed	Affiliated University	Summary
Dr Sally Campbell (PhD)	The Australian experience of inherited and acquired bleeding disorders	September 2024	Monash University	The PhD examined multiple issues with rare inherited and acquired bleeding disorders. This included complications of treatment of severe and moderate haemophilia A/B such as central venous catheters in children and Pseudotumour in potentially under-treated patients. As well as a study looking at the national data on efficacy and safety of porcine FVIII in acquired haemophilia, and the haemostatic efficacy of Emicizumab in very active patients.



Research Awards and Achievements

Recipient (RBWH staff in bold)	Award	Event
<b>Sally Campbell</b>	Appointment as Clinical Research Consultant – AHDCO 2024-2026	2024 Australian Haemophilia Centre Directors' Organisation (AHDCO)
<b>Robyn Western, Renee Campbell</b>	Best Nurses Poster Award 2024	BLOOD24 - HSANZ

Research Grants

Investigator Names (RBWH staff in bold)	RBWH Departments / Research Groups	Research Project Title	Granting Body	Total Awarded (whole all years)	Length of Awards in years and years active
<b>Dr Ashleigh Scott</b>	Haematology/BMT Cancer Care Services	Implementing molecular imaging and microbial biomarkers to deliver precision medicine in cancer immunotherapy	MNHHS Clinician Research Fellowship	0.4 FTE	3 years, 2024-27
<b>Dr Ashleigh Scott</b>	Haematology/BMT Cancer Care Services	Harnessing the gut microbiome to improve stem cell transplant outcome	NHMRC Ideas Grant (CI-D)	1,719,763.60	3 years, 2024-2027
<b>A/Prof Andrea Henden</b>	Haematology/BMT Cancer Care Services	Micro Fibre CAR	2023 Gilead Australia Research Fellowship	\$60,000	1 year, 2023 - 2024
<b>A/Prof Andrea Henden</b>	Haematology/BMT Cancer Care Services	Solving problems in Chimeric Antigen Receptor T cell Immunotherapy	2023 SERTA Project Grant	\$75,000	1 year, 2023-2024
<b>A/Prof Andrea Henden</b>	Haematology/BMT Cancer Care Services	Unlocking the gut microbiome to track the spread of AMR genes and pathogens	2023 MRFF Global Health Grant	\$1,990,643	5 years, 2023-2027

Investigator Names (RBWH staff in bold)	RBWH Departments / Research Groups	Research Project Title	Granting Body	Total Awarded (whole all years)	Length of Awards in years and years active
<b>Professor Steven Lane</b>	Haematology/BMT Cancer Care Services	Translation of genetic findings to improve outcomes for patients with blood cancers.	NHMRC Investigator Grant, L1.	\$1,913,403	5 years, 2021-2025
<b>Professor Steven Lane</b>	Haematology/BMT Cancer Care Services	Rare Cancers and Unmet Need: MoST-LLy, Molecular Screening and Therapeutics Leukaemia and Lymphoma	MRFF Clinical Trials Activity	\$2,688,736.40	5 years, 2021-2025
<b>Professor Steven Lane, A/Prof Siok Tey, Glen Kennedy, Andrea Henden</b>	Haematology/BMT Cancer Care Services / QIMRB	ACRF Centre for Optimised Cancer Therapy	Australian Cancer Research Foundation - ACRF	\$2,000,000.00	5 years, 2023-2028
<b>Dr Ashleigh Scott</b>	Haematology/BMT Cancer Care Services	Immune cell profiling using spatial transcriptomics in gastrointestinal graft versus host disease	MNHHS Collaborative Research Grant (CRG)	\$50,000.00	2 years, 2022-2024
<b>Dr Glen Kennedy</b>	Haematology/BMT Cancer Care Services	QCOG Cancer Clinical Trial Data Manager Grant 2022	Queensland Clinical Oncology Group	\$64,000.00	1 year, 2024

## RBWH Department / Research Group Led Research Activity

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited
<b>Andrea Henden</b>	Ashleigh Scott, Caroline McNamara, Glen Kennedy, Kirk Morris, Siok Tey, Stewart Hunt	T2MR - Performance of emerging microbiological techniques for the diagnosis of severe infections in neutropenic patients with haematological malignancies	3	36
<b>Andrea Henden</b>	Cameron Curley, Siok Tey, Elango Subramonia Pillai, Ashleigh Scott, Steven Lane, Glen Kennedy, Jason Butler, James Morton, Heshani Mediwake	"Micro GVHD" - Faecal Microbial Transplantation for Graft-Versus-Host Diseases	3	44
<b>Andrea Henden</b>	Cameron Curley, Siok Tey, Elango Subramonia Pillai, Ashleigh Scott, Steven Lane, Cheryl Hutchins, Glen Kennedy, Jason Butler, Heshani Mediwake, Kirk Morris	CARTOS - Chimeric Antigen Receptor-T cell Observational Study	3	7
<b>Andrea Henden</b>	Cameron Curley, Siok Tey	COVEM - COVID-19 Vaccine Efficacy in patients with Haematological Malignancy	3	0
<b>Andrea Henden</b>	Glen Kennedy, Cameron Curley, Jason Butler, Elango Subramonia Pillai, Ashleigh Scott, Kirk Morris, Nicholas Weber, Caroline McNamara, Stewart Hunt, Nilu Perera, Siok Tey, Ross Lindell-Innes	KITE 0601 - A Phase 1 Open-label, Single Arm, Multicenter Study Evaluating the Safety and Efficacy of KITE-197 in Subjects with Relapsed or Refractory Large B-cell Lymphoma	3	0



Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited
<b>Andrea Henden</b>	Cameron Curley, Caroline McNamara, Elango Subramonia Pillai, Glen Kennedy, Jason Butler, Kirk Morris, Nicholas Weber, Nilu Perera, Siok Tey, Stephen Boyle, Stewart Hunt, Ross Lindell-Jones	Janssen Mono CAR - A Phase 1b Multicenter, Open-Label, Study of JNJ-90009530, an Autologous Anti-CD20 CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (90009530LYM1001)	3	1
<b>Ashleigh Scott</b>	Andrea Henden, Cameron Curley, Elango Subramonia Pillai, Glen Kennedy, Stewart Hunt, Ross Lindell-Innes, Jason Butler, Siok Tey, Ross Lindell-Jones	ANZHIT2 - A multi-centre phase II, Australian and New Zealand, exploratory study of amendments to conditioning regimens in haplo-identical stem cell transplantation	3	2
<b>Ashleigh Scott</b>	Antiopi Varelias, Andrea Henden, Quan Nguyen, Glen Kennedy, Sunil Lakhani, Joshua Satchwell	Immune cell profiling using spatial transcriptomics in gastrointestinal graft versus host disease	3	0
<b>Ashleigh Scott</b>	Cameron Curley, Glen Kennedy, Siok Tey, Andrea Henden, Elango Subramonia Pillai, Jason Butler, Stewart Hunt, Ross Lindell-Jones	CYP-GVHD-P2-01 - Multicenter, Randomized, Double-blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of CYP-001 in Combination with Corticosteroids vs Corticosteroids Alone for the Treatment of High-Risk Acute Graft Versus Host Disease	3	2
<b>Glen Kennedy</b>	Sanjoy Paul, David Ritchie, David Gottlieb, John Moore, Julian Cooney, Simon Durrant, Jason Butler, James Morton, Ashish Misra, Siok Tey, Elango Subramonia Pillai, Cameron Curley	TCZ III - A phase III randomized study of humanized anti-IL-6 receptor antibody Tocilizumab (TCZ) to prevent development of acute graft versus host disease (GVHD) post HLA-matched allogeneic haematopoietic progenitor cell transplantation (HPCT)	3	0
<b>Glen Kennedy</b>	Andrea Henden, Ashleigh Scott, Cameron Curley, Elango Subramonia Pillai, Jason Butler, Siok Tey	NKARTA - A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects with B-cell Malignancies	3	1
<b>Caroline McNamara</b>	Stewart Hunt, Steven Lane, Kirk Morris, Luani Barge, Ross Lindell-Innes, Michelle Spanevello, Cameron Curley, Nilu Perera, Ashleigh Scott, Nicholas Weber, Becky Leung	AMGEN Golden Gate - Phase 3 Randomized, Controlled Study of Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia With Safety Run-in	3	1
<b>Caroline McNamara</b>	Steven Lane, Kirk Morris, Nicholas Weber, Ashleigh Scott, Cameron Curley	Geron IMPACT MYF3001 - A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Refractory to Janus Kinase (JAK) Inhibitor	3	1
<b>Caroline McNamara</b>	Steven Lane, Kirk Morris, Ashleigh Scott, Cameron Curley, Nilu Perera, Stewart Hunt, Elango Subramonia Pillai, Siok Tey, Andrea Henden	INCYTE INCA - A Phase 1, Open-Label, Multicenter Study of INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms	3	3

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited
<b>Jane Mason</b>	Sally Campbell, Nicholas Weber	CSL222_3005 IX-TEND - A Phase 3b, Open label, Multicenter, Single-dose Study Investigating Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy Administered to Adult Subjects with Severe or Moderately Severe Hemophilia B with Detectable Pretreatment AAV5 Neutralizing Antibodies	3	1
<b>Jane Mason</b>	Sally Campbell, Nicholas Weber, Antoinette Runge, Michelle Spanevello	Vega Therapeutics VGA039-CP001 VIVID-2 - A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of VGA039 Following Intravenous or Subcutaneous Administration of Single Ascending Doses in Healthy Adults and Adult Patients with von Willebrand Disease	3	1
<b>Jane Mason</b>	Michelle Spanevello, Sally Campbell	Pfizer C0371004 - An open-label, non-investigational product, multi-center, lead-in study to evaluate prospective efficacy and selected safety data of current Factor IX (FIX) or factor VIII (FVIII) prophylaxis replacement therapy in the usual care setting of moderately severe to severe adult hemophilia B participants (FIX:C=2%) who are negative for neutralizing antibodies to adeno-associated virus vector Spark100 (benegene-1) and moderately severe to severe hemophilia A adult participants (FVIII:C=1%) who are negative for neutralizing antibodies to adeno-associated virus vector 6 (AAV6), prior to the respective therapeutic phase 3 gene therapy studies	3	0
<b>Jane Mason</b>	Michelle Spanevello, Sally Campbell	Pfizer C0371002 - Phase 3, open label, multi-cohort, multi-center study of FIX gene transfer with PF-06838435 (rAAV-Spark100-hFIX-Padua) in adult male participants with moderately severe to severe hemophilia B (FIX:C=2%) (BeneGene-2)	3	0
<b>Jason Butler</b>	Cameron Curley, Glen Kennedy, Elango Subramonia Pillai, Siok Tey, Nicholas Weber, Kirk Morris, Ashleigh Scott	Novartis E2202 ELARA - A Phase II, single arm, multicenter open label trial to determine the efficacy and safety of tisagenlecleucel (CTL019) in adult patients with refractory or relapsed follicular lymphoma	3	0
<b>Jason Butler</b>	Ashleigh Scott, Nicholas Weber, Cameron Curley, Elango Subramonia Pillai, Kirk Morris	PLIMATH - A multi-centre Phase II study to determine the response kinetics, safety and efficacy of pembrolizumab as frontline treatment of patients with Hodgkin Lymphoma considered unsuitable for ABVD	3	0
<b>Jason Butler</b>	Cameron Curley, Simon Durrant, Kirk Morris, Elango Subramonia Pillai, Siok Tey, Nicholas Weber, Glen Kennedy	Acerta 308 ECHO – A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of BR alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell 3Lymphoma	3	0
<b>Jason Butler</b>	Ashleigh Scott, Cameron Curley, Elango Subramonia Pillai, Nicholas Weber, Kirk Morris	Genmab GCT3013-01 - A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma	3	0
<b>Jason Butler</b>	Andrea Henden, Ashleigh Scott, Cameron Curley, Elango Subramonia Pillai, Glen Kennedy, Siok Tey, Ross Lindell-Jones	Janssen CARTITUDE 4 - A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA, vs Pomalidomide, Bortezomib and Dexamethasone (PvD) in Subjects with Relapsed and Lenalidomide-Refractory Multiple Myeloma	3	0

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited
<b>Jason Butler</b>	Andrea Henden, Ashleigh Scott, Cameron Curley, Elango Subramonia Pillai, Glen Kennedy, Siok Tey, Ross Lindell-Jones	Janssen CARTITUDE 5 - A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants with Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy	3	0
<b>Jason Butler</b>	Andrea Henden, Ashleigh Scott, Cameron Curley, Elango Subramonia Pillai, Glen Kennedy, Siok Tey, Ross Lindell-Jones	EMN 28 CARTITUDE 6 - A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in Participants with Newly Diagnosed Multiple Myeloma who are Transplant Eligible	3	4
<b>Jason Butler</b>	Ashleigh Scott, Andrea Henden, Cameron Curley, Glen Kennedy, Elango Subramonia Pillai, Nilu Perera, Stewart Hunt, Nicholas Weber, Kirk Morris, Caroline McNamara, Rebecca Cleary	BMS KarMMA - A Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Idecabtagene Vicleucel (Ide-Cel) with Lenalidomide (LEN) Maintenance Versus Lenalidomide Maintenance Therapy Alone in Adult Participants with Newly Diagnosed Multiple Myeloma (NDMM) Who Have Suboptimal Response After Autologous Stem Cell Transplantation (ASCT)	3	0
<b>Jason Butler</b>	Andrea Henden, Ashleigh Scott, Kirk Morris, Cameron Curley, Nicholas Weber, Nilu Perera, Elango Subramonia Pillai, Glen Kennedy, Siok Tey, Stewart Hunt	KITE ZUMA 23 - A Phase 1 Open-label, Single Arm, Multicenter Study Evaluating the Safety and Efficacy of KITE-197 in Subjects with Relapsed or Refractory Large B-cell Lymphoma	3	0
<b>Sally Campbell</b>	Jane Mason	Rare Factor Deficiencies & AT Knockdown - Evaluating the in vitro effect of antithrombin (AT) inhibition on thrombin generation in patients with severe Factor V, Factor VII or Factor XI deficiencies by AT-antibodies	3	1
<b>Nicholas Weber</b>	Nilu Perera, Stewart Hunt, Kirk Morris, Jason Butler, Ross Lindell-Jones	REGENERON LINKER - Open-Label Randomized study to evaluate linvoseltamab versus EPd in Relapsed/Refractory Multiple Myeloma - RGN5458-ONC-2245 LINKER-MM3	3	3
<b>Nicholas Weber</b>	Jason Butler, Ashish Misra, Kirk Morris, Cameron Curley, Elango Subramonia Pillai	Beigene 304 - An International, Phase 3, Open-label, Randomized Study of BGB 3111 Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	3	0
<b>Nicholas Weber</b>	Jason Butler, Kirk Morris	DREAMM 7 - A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared with the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants with Relapsed/Refractory Multiple Myeloma	3	0

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited
<b>Siok Tey</b>	Glen Kennedy, Cameron Curley, Jason Butler, Elango Subramonia-Pillai, Ashleigh Scott, Simon Durrant, James Morton	CSL Behring MODULAATE - A Phase 2/3, Multicenter, randomized, Double-blind, placebo-controlled, study to evaluate the safety and efficacy of Alpha-1 AntiTrypsin for the prevention of graft-versus-host disease in patients receiving hematopoietic cell transplant	3	0
<b>Siok Tey</b>	Glen Kennedy, Simon Durrant, James Morton, Jason Butler, Elango Subramonia-Pillai, Cameron Curley, Ashish Misra	IL-17 – Observational study of IL-17-related cytokines in stem cell transplantation	3	0
<b>Siok Tey</b>	Glen Kennedy, Cheryl Hutchins	TREG Apheresis - Developing a method to generate regulatory T cells from healthy donors	3	0
<b>Siok Tey</b>	Glen Kennedy, Simon Durrant, James Morton, Jason Butler, Elango Subramonia-Pillai, Cameron Curley, Ashish Misra	IR Auto – Observational study of immune reconstitution in patients undergoing autologous stem cell transplantation	3	0
<b>Siok Tey</b>	Glen Kennedy, Simon Durrant, James Morton, Jason Butler, Elango Subramonia-Pillai, Cameron Curley, Ashish Misra	HAPLO - A Phase I Study of Haploidentical Haematopoietic Stem Cell Transplantation with Add-Back of Donor T Cells Transduced with Inducible Caspase 9 Suicide Gene in Patients with Poor Risk Haematological Malignancies	3	0
<b>Siok Tey</b>	Glen Kennedy, Cheryl Hutchins	Generating Chimeric Antigen Receptor (CAR T) cells from healthy volunteers	3	0
<b>Siok Tey</b>	Andrea Henden, Ashleigh Scott, Cameron Curley, Cheryl Hutchins, Elango Subramonia Pillai, Glen Kennedy, Heshani Mediwake, James Morton, Jason Butler, Kari Mudie;	Phase I Clinical Trial of MB.CART19.1 CD19 Chimeric Antigen Receptor (CAR) T Cells in Relapsed or Refractory CD19-Positive Haematological Malignancy	3	7
<b>Steven Lane</b>	Glen Kennedy	P1382 - Examination of genes that control the growth and survival of blood cancers	3	0
<b>Steven Lane</b>	Elango Subramonia Pillai, Cameron Curley, Nicholas Weber, Kirk Morris, Caroline McNamara.	FORTREA APTIVATE APTOSE - A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HM43239 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)	3	0

## Collaborative Research Activity Involving RBWH Department / Research Group

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited in 2024
<b>Ashleigh Scott</b> Monash University	<b>Ashleigh Scott</b>	AAR: Aplastic Anaemia and Other Bone Marrow Failure Syndromes Registry	3	4
<b>Elango Subramonia Pillai</b> Monash University, Peter MacCallum Cancer Centre	<b>Michelle Spanevello, Jason Butler, Cameron Curley, Kirk Morris, Nicholas Weber, Ashleigh Scott</b>	TREATT: A double blind, randomised controlled trial evaluating the safety and efficacy of tranexamic acid in patients with haematological malignancies with severe thrombocytopenia	3	0



Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited in 2024
<b>Glen Kennedy</b> ALLG (The Australasian Leukaemia & Lymphoma Group)	<b>Nicholas Weber, Cameron Curley, Jason Butler, Kirk Morris, Elango Subramonia Pillai, Simon Durant, Steven Lane</b>	AML M16 – Sorafenib in Combination with Intensive Chemotherapy for Previously Untreated Adult FLT3-ITD Positive AML: A Phase 2 Randomised Double-Blind Placebo Controlled Multi-Centre Study	3	0
<b>Caroline McNamara</b> ALLG	<b>Cameron Curley, Jason Butler, Elango Subramonia Pillai, Steven Lane, Kirk Morris, Nicholas Weber,</b>	ALLG AML M24 - A phase 3, multicenter, open-label, randomized, study of gilteritinib versus midostaurin in combination with induction and consolidation therapy followed by one year maintenance in patients with newly diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapy	3	0
<b>Glen Kennedy</b> ALLG	<b>Cameron Curley, Jason Butler, Elango Subramonia Pillai, Steven Lane, Kirk Morris, Nicholas Weber, Simon Durant</b>	ALLG NBCR – Australasian Leukaemia and Lymphoma Group Acute Myeloid Leukaemia National Blood Cancer Registry	3	3
<b>Steven Lane</b> ALLG	<b>Cameron Curley, Jason Butler, Nicholas Weber, Elango Subramonia Pillai</b>	ALLG APL5: A phase 1 pharmacokinetic evaluation of oral arsenic trioxide in previously untreated patients with acute promyelocytic leukaemia	3	0
<b>Steven Lane</b> ALLG	<b>Cameron Curley, Jason Butler, Kirk Morris, Nicholas Weber, Elango Subramonia Pillai, Simon Durrant, Glen Kennedy</b>	AML M21: A phase Ib/II clinical evaluation of Ponatinib in combination with 5-azacitidine in FLT3-ITD positive acute myeloid leukaemia	3	0
<b>Steven Lane</b> ALLG	<b>Caroline McNamara;Elango Subramonia Pillai;Kirk Morris;Nicholas Weber;</b>	ALLG CML 13 ASCEND - A single arm phase II study to evaluate the efficacy of asciminib in newly diagnosed patients with chronic phase chronic myeloid leukaemia	3	0
<b>Steven Lane</b> ALLG	<b>Cameron Curley, Jason Butler, Kirk Morris, Nicholas Weber, Elango Subramonia Pillai</b>	LS17 REGALLIA: Studies to delineate the molecular and genomic basis of high risk ALL (Registry of Acute Lymphoblastic Leukaemia in Australasia and Associated Correlative Studies)	3	0
<b>Steven Lane</b> SAHMRI	<b>Andrea Henden, Cameron Curley, Caroline McNamara, Kirk Morris, Nicholas Weber</b>	PREACH-M - Precision Medicine for Chronic Myelomonocytic Leukaemia: A phase II Trial Studying the Efficacy of Lenzilumab and High Dose Ascorbate with Azacitidine Based on Molecular Profiling	3	0
<b>Siok Tey</b> Westmead Institute of Medical research	<b>Ashleigh Scott, Andrea Henden, Cameron Curley, Elango Subramonia Pillai, Jason Butler</b>	R3ACT Randomised (R3R) - A randomised trial of most closely HLA-matched third-party donor-derived virus-specific cytotoxic T-lymphocytes in patients with untreated viral infection post-allogeneic stem cell transplantation	3	0

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited in 2024
<b>Siok Tey</b> ALLG	<b>Jason Butler, Cameron Curley, Simon Durrant, Glen Kennedy, Ashleigh Scott, James Morton, Elango Subramonia Pillai, Andrea Henden</b>	ALLG BM12 CAST: Study of using Cyclophosphamide After Sibling-donor allogeneic stem-cell Transplantation (CAST) in patients with acute leukaemia and myelodysplasia: a randomised study comparing cyclosporin and methotrexate to cyclosporin and post-transplantation cyclophosphamide for graft-versus-host disease prophylaxis.	3	0
<b>Nicholas Weber</b> MNHHS, QIMRB	<b>Andrea Henden, Steven Lane, Kirk Morris, Cameron Curley, Ashleigh Scott, Elango Subramonia Pillai, Caroline McNamara</b>	Immune profiling of haematological malignancies	3	0
<b>Nicholas Weber</b> ALLG	<b>Kirk Morris, Caroline McNamara, Elango Subramonia Pillai, Cameron Curley, Ross Lindell-Jones</b>	ALLG HD13 RADAR - A randomised phase III trial with a PET response adapted design ABVD +/- ISRT and A2VD +/- ISRT in patients with previously untreated stage IA/IIA Hodgkin lymphoma	3	3
<b>Nicholas Weber</b> The Myeloma and Related Diseases Registry	<b>Jason Butler</b>	MRDR - Myeloma and Related Diseases Registry	3	31
<b>Nicholas Weber</b> AMaRC (Australasian Myeloma Research Consortium)	<b>Kirk Morris, Caroline McNamara, Jason Butler,</b>	AMARC 19-02 BelaCarD - A phase I/II single arm study of combination Belantamab Mafodotin, Carfilzomib, Dexamethasone in patients with early relapsed multiple myeloma	3	0
<b>Nicholas Weber</b> AMaRC (Australasian Myeloma Research Consortium)	<b>Ashleigh Scott, Cameron Curley, Jason Butler</b>	AMARC VCDD - A randomized phase 2 study of bortezomib, cyclophosphamide and dexamethasone induction (VCD) compared with VCD and daratumumab induction followed by daratumumab maintenance (VCDD) for the initial treatment of transplant ineligible patients with multiple myeloma	3	1
<b>Nicholas Weber</b> AMaRC (Australasian Myeloma Research Consortium)	<b>Ashleigh Scott, Cameron Curley, Jason Butler, Ross Lindell-Jones</b>	AMARC RIDDLE-M-X trial - Risk Directed Front-Line Therapy for Multiple Myeloma incorporating Selinexor	3	5
<b>Steven Lane</b> The University of Sydney	<b>Nicholas Weber, Cameron Curley, Kirk Morris</b>	MoST Framework - The Cancer Molecular Screening and Therapeutics (MoST) Program - A framework protocol for multiple, parallel, signal-seeking clinical studies of novel molecularly targeted therapies for patients with advanced cancer and unmet clinical need.	2	2
<b>Steven Lane</b> Australian Genomic Cancer Medicine Group, OMICO, NHMRC	<b>Andrea Henden, Cameron Curley, Caroline McNamara, Kirk Morris, Nicholas Weber</b>	MoST LLY 15 AZ - A single arm, open label, signal seeking, phase II trial of the activity of Durvalumab in combination with Acalabrutinib in patients with high-grade B cell lymphoma	2	1
<b>Steven Lane</b> Australian Genomic Cancer Medicine Group, OMICO, NHMRC	<b>Andrea Henden, Cameron Curley, Caroline McNamara, Kirk Morris, Nicholas Weber</b>	MoST LLY 16 BGB - AZ - A Single arm, open label, signal seeking, phase II trial of pamiparib in patients with relapsed/refractory myeloid haematological malignancy with aberrant germline or somatic DNA repair pathway function	2	0

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited in 2024
<b>Jason Butler</b> PMCC (Peter MacCallum Cancer Centre)	<b>Cameron Curley;Elango Subramonia Pillai;Kirk Morris;Ashleigh Scott;Siok Tey;Andrea Henden; Ross Lindell-Jones</b>	PMCC COALITION - A multicentre, parallel arm, open-label trial of frontline R-CHOP/Pola-RCHP and glofitamab in younger, higher risk patients with diffuse large B cell lymphoma (DLBCL)	3	0

## Research Publications

### Authors

Investigator	ORCID ID	Investigator	ORCID ID
Sally Campbell	0000-0002-1421-745X	Steven Lane	0000-0002-8050-6209
Caroline McNamara	0000-0002-1116-9747	Jane Mason	0000-0002-8320-2884
Joseph Noye	0000-0002-4422-3375	Stewart Hunt	0000-0002-4555-6964
Jason Butler	0000-0002-6422-4404	Nilu Perera	0000-0002-4752-0551
Kirk Morris	0009-0003-2446-1098	A/Prof Glen Kennedy	0000-0002-7171-0435
Antoinette Runge	0009-0000-7543-3706	Andrea Henden	0000-0003-2261-169X
Ross Lindell-Innes	0009-0004-4044-1369	Siok Tey	0000-0001-9567-382X
Michelle Spanevello	0000-0003-1498-7822	Ashleigh Scott	0000-0001-5574-6713
Nick Weber	0000-0001-6341-2537		

### Publications in 2024

**Journal Articles (RBWH staff or consumers in bold)**

Fleming, S, **Scott, AP.**, and Hamad, N., et al. ANZTCT Practice Statement: Veno-occlusive disease diagnosis and management. Internal Medicine Journal, in print

Sheehy, J., **Scott, AP., Henden, A., Kennedy, G.,** Redmond, A., Stewart, A. Low rates of complications and beta-lactam resistance in viridans group streptococci bloodstream infection among cancer patients receiving chemotherapy. Journal of Antimicrobial Chemotherapy, in print

Dreyling, M., Fowler, N.H., Dickinson, M., Martinez-Lopez, J., Kolstad, A., **Butler, J.** et al. Durable responses after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update Blood (2024) 143 (17): 1713–1725

Boots, **R., Scott, AP.**, et al. Virtual reality experience in bone marrow transplant treatment – technical evaluation. BMC Digit Health 2, 6 (2024)

**Perera N, Baidya S, Weber N, Mudie K, Butler J, Curley C, Henden A, Hunt S, Subramoniapillai E, Tey SK, Kennedy GA, Scott AP.** Granulocyte transfusion supportive care for prolonged cytopenias post CD19 CAR T cell therapy. Transfusion. 2024 Apr;64(4):762-765. doi: 10.1111/trf.17793. PMID: 38593296

Madan B, Ozelo MC, Raheja P, Symington E, Quon DV, Leavitt AD, Pipe SW, Lowe G, Kenet G, Reding MT, **Mason J,** Wang M, von Drygalski A, Klamroth R, Shapiro S, Chambost H, Dunn AL, Oldenburg J, Chou SC, Peyvandi F, Millar CM, Osmond D, Yu H, Dashiell-Aje E, Robinson TM, Mahlangu J. Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A. J Thromb Haemost. 2024 Apr 11:S1538-7836(24)00184-3. doi: 10.1016/j.jtha.2024.04.001. Epub ahead of print. PMID: 38614387

Bruedigam C, Porter AH, Song A, Vroeg in de Wei G, Stoll T, Straube J, Cooper L, Cheng G, Kahl VFS, Sobinoff AP, Ling VY, Jebaraj BMC, Janardhanan Y, Haldar R, Bray LJ, Bullinger L, Heidel FH, **Kennedy GA,** Hill MH, Pickett HA, Abdel-Wahab O, Hartel G, **Lane SW.** Imetelstat-mediated alterations in fatty acid metabolism to induce ferroptosis as therapeutic strategy for acute myeloid leukemia. Nature Cancer 2023, <https://doi.org/10.1038/s43018-023-00653-5>

Lineburg KE, Leveque-El Mouttie L, Hunter CR, Le Texier L, McGirr C, Teal B, Blazar BR, **Lane SW,** Hill GR, Levesque J, MacDonald KPA. Autophagy prevents graft failure during murine Graft vs. Host Disease. Blood Adv 2024, In Press

### Journal Articles (RBWH staff or consumers in bold)

Ekwe, A.P., Au, R., Zhang, P., McEnroe, B.A., Tan, M.L., Saldan, A., **Henden, A.S., Hutchins, C.J., Henderson, A., Mudie, K., Kerr, K., Fuery, M., Kennedy, G.A., Hill, G.R., & Tey, S.K.** Clinical grade multiparametric cell sorting and gene-marking of regulatory T cells. International Society for Cell & Gene Therapy. 2024 Feb();1465-3249. doi:10.1016/j.jcyt.2024.02.023. Epub 2024 Mar 5

Young G, Lassila R, **Mason J**, Prasca S. JTH in the Clinic: Deconstructing the ISTH Hemophilia Guidelines for the Clinician. J Thromb Haemost. 2024 Nov 29:S1538-7836(24)00705-0. doi: 10.1016/j.jtha.2024.11.015. Epub ahead of print. PMID: 39617189

**Runge A**, Mason J. Challenges of platelet electron microscopy in the diagnosis of platelet delta storage pool disorder. Pathology. 2024 Oct 15:S0031-3025(24)00248-4. doi: 10.1016/j.pathol.2024.08.007. Epub ahead of print. PMID: 39537513

Leavitt AD, Mahlangu J, Raheja P, Symington E, Quon DV, Giermasz A, López Fernández MF, Kenet G, Lowe G, Key NS, Millar CM, Pipe SW, Madan B, Chou SC, Klamroth R, **Mason J**, Chambost H, Peyvandi F, Majerus E, Pepperell D, Rivat C, Yu H, Robinson TM, Ozelo MC. Efficacy, safety, and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A in the phase 3 GENE8-1 trial. Res Pract Thromb Haemost. 2024 Oct 30;8(8):102615. doi: 10.1016/j.rpth.2024.102615. PMID: 39687929; PMCID: PMC11647608

Pazhakh, V., Fox, L., Den Elzen, N., Emerson, M., Cohen, S., Bryan, T., Norris, Kevin, Baird, Duncan, Cochrane, T., Mackintosh, J., **Scott, AP** and Blombery, P. A novel TERT variant associated with a telomere biology disorder and challenges in variant classification. Eur J Haematol, 2024, in print.

### Oral Presentations (RBWH staff or consumers in bold)

**Mason J**: Queensland Haemophilia Centre Education Day, Brisbane Australia, June 6, 2024 – “Acquired Haemophilia A” and “New Therapies, unmet needs, prospects and the conclusion of the Education Day”

**Allan M**: Queensland Haemophilia Centre Education Day, Brisbane Australia, June 6, 2024 – “Gene Therapy Clinical Trials”

**McLean A**: Genesis Care Specialist Cancer Nurses Forum at Milton, Brisbane – 13 June 2024 – “CAR T Cell Therapy at the RBWH: A Patient Journey”

**Klever, A**. Pregnancy and Delivery Management of women who carry the Haemophilia Gene in Queensland. Blood conference, October 2024, Brisbane

**Pastore, G**. Successful cardiac surgery in 3 patients with Haemophilia A on Emicizumab. Blood conference, October 2024, Brisbane.

### Keynote or Plenary Lectures given in 2024

Date	Title
5/3/2024	<b>Tey S</b> : New Direction in Leukaemia Research – Adelaide – 5 March 2024 – “Update of CAR T cell therapy for the treatment of blood cancers: milestones, obstacles and future directions”
11/5/2024	<b>Butler J</b> : Malaysian Society of Transplantation Annual Scientific Meeting 11th May 2024 - "Emerging options in the management of Graft V Host Disease"
22/3/2024	<b>Spanevello M</b> : Thoracic Society of Australia and New Zealand Society of Respiratory Science 2024 – “Difficult anticoagulation situations in Pulmonary Embolism”
3/5/2024	<b>Spanevello M</b> : Annual Scientific Meeting of the Australian and New Zealand College of Anaesthetists and The Faculty of Pain Medicine 2024 – “Obstetric Haemorrhage – The perspective of the Haematologist”
31/5 - 1/6/2024	<b>Henden A</b> : Gilead ACTIVATE CAR T Educational Workshop 31 May - 1 June 2024 – “Advances in CAR T cell Therapies; Updates and perspective from ASH 2023”
22-26/6/2024	<b>Klever A</b> : 32nd Congress of the International Society on Thrombosis and Haemostasis, Bangkok, Thailand from June 22 – 26, 2024. – “Nursing management of patients with Acquired Haemophilia A”
28/10/2024	<b>Campbell, S</b> . Novel therapies - where do they sit in the haemophilia space. Blood conference, October 2024, Brisbane.
28/10/2024	<b>Scott AP</b> , Blood 2024, Presidential Symposium (oral plenary). MRI and Neurocognitive Assessment of Chemobrain in Acute Myeloid Leukaemia



## Radiation Oncology



**Dr Penny Mackenzie**  
**Director Radiation Oncology**

The culture of inter-disciplinary collaboration and advancing technology in research remained strong for radiation oncology in 2024. The aim and focus of the Radiation Oncology Research group is to promote, support and drive innovation, promote quality initiatives and ensure quality improvement projects deliver evidence-based practice, to ensure safe treatment delivery.

As new and emerging technologies are rapidly being assimilated into daily practice, the focus of research outcomes is to implement new technology in a scientific manner. Quality assurance and research into new technology is important to ensure, precision radiotherapy is delivered in a safe, efficient, and cost-effective manner.

During 2024 the Radiation Oncology team continued to develop a broad research program with 7 active research grants that provide financial support for research activities in 2024. The Radiation Oncology department are lead investigator for 18 current research projects and have joined in collaboration with other RBWH departments or researchers from external organisations, on 24 research projects. The Radiation Oncology Department have been very active with regards to research publications and journal articles. The department currently have 9 supervised Post-Graduate Research Students, including RBWH staff enrolled in a research higher degree (HDR), undertaking a research project with our department, or being supervised by RBWH employees.

Some of the departments 2024 achievements include:

- Dr Penny Mackenzie and team were awarded a Medical Research Future Fund (MRFF) – Applied Research in Health grant titled, “Delivering better care for older Australians with cancer”. This project will be led by Prof Meera Agar at the University of Technology in Sydney. The \$1,468,223 grant will be used to support this project over the next 4 years.
- The 2024 Metro North Research Excellence awards were held in September 2024, with several teams from Cancer Care Services finalists in their categories. These include Tanya Kairn and Scott Crowe for a Discovery and Innovation Award for their work developing the World's First Radiotherapy 3D Printing Textbook, and Cancer Care Services Clinical Research Unit for the Research Support Award for their innovative support of research across Metro North
- Robyn Cheuk, Scott Crowe, and Rachael Wilks from the CCS Department of Radiation Oncology, as well as staff from STARS and the Comprehensive Breast Cancer Institute, won the Transforming Health Award at the 2024 Queensland Health Awards for Excellence, for their Breast Cancer Intraoperative Radiation Therapy (IORT) service.

Looking ahead, 2025 will be another active year for research. Several manuscripts are in progress and will be published in the near future. In-house projects led by our radiation therapists, physicists and national/international collaborative projects introduced to the department by the Radiation Oncologists are being designed and rolled out in the coming months. Finally, we like to whole heartedly thank our patients who participate in our trials to make clinical research possible.

## Research Awards and Achievements

Recipient (RBWH staff in bold)	Award	Event
Breast Cancer Intra-Operative Radiation Therapy Team	Queensland Health Award for Excellence – Transforming Health	Queensland Health Awards for Excellence

## Research Grants

Investigator Names (RBWH staff in bold)	RBWH Departments / Research Groups	Research Project Title	Granting Body	Total awarded (whole all years)	Length of Awards in years and years active
K Fong, I Yang, H Marshall, R Bowman, R O'Rourke, P Valery, E Stone, R Manser, K Canfell, M Weber, G Garvey, S Lam, M Tammemagi, S Sabesan, Z Otty, F Brims, A McWilliams, B Page, J De Laat, S Hambleton, <b>G Pratt, P Chan</b> , M Windsor, R Naidoo, B Hughes, Z Lwin, K Hopcraft, M Toombs, P Fogart, P Tobias, B Bartholmai, F Maldonado, F Martignano, S Conticello, P Grogan, L Passmore, A Dent, G Olive, B Parris, H O'Farrell, K Chee	MNH, DRO, DM	Improving outcomes for people with and at risk of lung cancer	Australian Cancer Research Foundation (ACRF)	\$2,000,000	4 years, 2022-2025
Agar M, Hayen A, Viney R, Knox N, Vinod S, Krasovitsky M, Blackberry I, Steer C, Moth E, Blinman P, Soo K, to T, Morris L, <b>Mackenzie P</b>	CCS DRO	Delivering better care for older Australians with cancer	Medical Research Future Fund (MRFF) – Applied Research in Health	\$1,468,223.13	4 years, 2024-2028
<b>Punyadeera C, Kenny L, Sriram S, Hughes B, Leo P</b>	CCS DRO, DMO	Multi-analyte liquid biopsy-based biomarkers for oropharyngeal cancer	NHMRC	\$763,417.40	4 years, 2022-2025
<b>Scott Crowe, Paul Charles, Elise Obereigner, Rachael Wilks, Lee Heseltine, Graeme Dickie, Catherine Bettington, Philip Chan, Steven Sylvander, Tanya Kairn, Glen Kennedy</b>	CCS DRO	Improving radiation oncology with 3D printing and Biofabrication	Herston Biofabrication Institute program grant	\$515,000	7 years, 2019-2025
Chamindie Punyadeera, <b>Lizbeth Kenny</b>	CCS DRO	A novel assay for early detection of minimal residual disease in head and neck cancer patients	Garnett Passe & Williams	\$375,000	4 years, 2022-2025
<b>Charles Lin</b>	CCS DRO	A prospective study investigating the efficacy and toxicity of definitive chemoradiation and immunotherapy (CRIO) in locally and / or regionally advanced cutaneous squamous cell carcinoma	Astra Zeneca	\$211,000	10 years, 2017-2027

Investigator Names (RBWH staff in bold)	RBWH Departments / Research Groups	Research Project Title	Granting Body	Total awarded (whole all years)	Length of Awards in years and years active
Mackenzie P	CCS DRO	Queensland Cancer Council Clinical Trial Data Manager Grant 2024	Queensland Cancer Council	\$39,000	1 year, 2024

## RBWH Department / Research Group Led Research Activity

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited
<b>Benjamin Chua</b>	<b>Rosalind Jeffree, Jacqui Keller,</b> Chamindie Punyadeera, <b>Zarnie Lwin,</b> Juliana Muller Bark, Lucas Trevisan Franca de Lima, Xi Zhang, Nuwan Tharanga Karunathilaka Wicramasingiha Arachchilage, Bryan Day (QIMR)	The use of non-invasive biomarkers in glioblastoma: A pilot study	3	30
<b>Charles Lin</b>	<b>Benjamin Chua, Lizbeth Kenny, Michelle Nottage, Brett Hughes,</b> Michele Teng, Paul Thomas	A prospective study investigating the efficacy and toxicity of definitive chemoradiation and immunotherapy (CRIO) in locally and / or regionally advanced cutaneous squamous cell carcinoma	3	15
<b>Jemma Walsh (nee Devereaux)</b>	<b>Jemma Blyth,</b> Elena Blyth, <b>Gregory Rattray,</b> Catriona Hargrave, Lisa Nissin, Julie Burbery	DIBH (Deep Inspiration Breath Hold)-BREaST Trial. Breath Hold Respiratory Endurance & Spirometry Training	3	40
<b>Emilie Crosier</b>	<b>Alice Grigg, Teresa Brown, Judy Bauer, Jeffrey Goh, Phillip Chan</b>	Dietary counselling to increase soluble fibre in patients with gynaecological cancer undergoing pelvic radiotherapy: a feasibility study	3	9
<b>Jemma Blyth, Kevina Choma</b>	<b>Michelle Grogan, Emily Simpson-Page, Naasiha Cassim,</b> Cathy Hargrave, <b>Scott Crowe</b>	Evaluation of a commercially available treatment bra during radiation therapy for breast cancer patients with large or pendulous breasts	3	10
<b>Scott Crowe</b>	<b>Tanya Kairn,</b> Katie McMahon, Louise Campbell, Clare Berry	Characterisation of anatomical variations in the central nervous system	4	13
<b>Scott Crowe</b>	<b>Paul Charles, Elise Obereigner,</b> Tania Poroa, <b>Jenna Luscombe, Rachael Wilks, Lee Heseltine, Graeme Dickie, Catherine Bettington, Philip Chan, Steven Sylvander, Tanya Kairn</b>	Improving radiation oncology with 3D printing and Biofabrication	4	N/A (~50 in HREC approved study so-far – retrospective)
<b>Scott Crowe</b>	Susie Cleland, <b>Sarah Maxwell,</b> Tania Poroa, <b>Paul Charles, Tanya Kairn</b>	Evaluation of 3D scanning systems for radiotherapy use	3	N/A (28 healthy volunteers)
<b>Scott Crowe</b>	<b>Liting Yu, Alex Livingstone, Samuel Peet, Tanya Kairn</b>	Characterising the relationship between radiotherapy treatment plan parameters and routine quality assurance test results	4	N/A
<b>Tanya Kairn</b>	<b>Philip Chan, Benjamin Chua, Scott Crowe, Jodi Dawes, Lizbeth Kenny, Charles Lin, Rob McDowall,</b> Tania Poroa	Anatomical displacements from oral positioning stents	4	N/A

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited
<b>Liting Yu</b>	<b>Tanya Kairn, Alex Livingstone, Scott Crowe,</b> Jamie Trapp	Structure based dose distribution comparison	4	N/A
<b>Charles Lin</b>	<b>Charles Lin, Megan Carroll,</b> Ryan Somerville, Sarah Grigg	Carcinoma of Head and Neck with Perineural spread: Outcomes After Skull Base Surgery and Adjuvant Radiotherapy	4	N/A (retrospective)
<b>Rachael Wilks</b>	<b>Scott Crowe, Tanya Kairn, Philip Chan, Robyn Cheuk</b>	Design of a patient-matched vaginal applicator for brachytherapy treatments	3	N/A
<b>Kate Stewart</b>	Izaak Millen, Crispen Chamunyonga, Neil O'Brien	Evaluation of patient position on heart and lung doses in breast cancer radiation therapy	4	N/A (retrospective)
<b>Kate Stewart</b>	<b>Samuel Peet, Jeremy Briggs, Benjamin Chua</b>	Evaluation of the correlation between optical and thermal surface tracking and kV x-ray imaging during cranial radiotherapy	4	N/A (retrospective)
<b>Scott Crowe</b>	Keya Amarsee, <b>Samuel Peet</b>	Dose calculation and comparison for superficial treatment modalities	4	N/A (retrospective) Awaiting HREA approval
<b>Scott Crowe</b>	<b>Tanya Kairn, Brodie Milsom</b>	Evaluation of dosimetric perturbation in and around synthetic scaffolds in breast radiotherapy	4	N/A
<b>Veronica Tippet</b>		Retrospective Audit of Image Guided Radiation Therapy Practices at the RBWH	4	Awaiting HREA approval
<b>Scott Crowe</b>	<b>Jemma Walsh, Nancy Yu, Philip Chan, Rachel Effene, Gregory Rattray, Tanya Kairn</b>	Radixact Synchrony performance data collection and analysis	4	N/A
<b>Kevina Choma</b>	<b>Kate Stewart,</b> Cathy Hargrave, Natalie Pollard, Grace Wright	An evaluation of accuracy and efficiency of ExacTrac Dynamic pre-positioning versus tattoo based positioning for chest radiation therapy	4	N/A (retrospective)
<b>Jemma Blyth</b>	<b>Kate Stewart, Philip Chan, Robyn Cheuk, Rachael Wilks, Craig Lancaster, Julie-Anne Outhwaite,</b> Clare Berry, Katie McMahon, Cathy Hargrave, Julie Burberry, Trinioty Murfett, Kylee Burton, Nuala Clinton, Sue Hewitt, Michelle Connors	Evaluation of magnetic resonance imaging protocols for radiation therapy treatment planning of gynaecological cancers	3 (awaiting HREA submission)	0 (awaiting HREA submission)

## Collaborative Research Activity Involving RBWH Department / Research Group

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited
A/Prof Hien Le	<b>Robyn Cheuk</b>	Australian Particle Therapy Clinical Quality Registry (ASPIRE)	2	0



Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited
Mariana Carbini	<b>Philip Chan</b>	An International, Prospective, Open-label, Multi-centre, Randomized Phase III Study comparing lutetium (177Lu) vipivotide tetraxetan (AAA617) versus Observation to delay castration or disease recurrence in adult male patients with prostate-specific membrane antigen (PSMA) positive Oligometastatic Prostate Cancer (OMPC) (PSMA-DC)	3	0
Dr Rachael Dodd	<b>Lizbeth Kenny</b>	Helping clinicians and patients make sense of HPV-related oropharyngeal cancer: implementation of an information resource. X24-0033	1	0
Mirvana Dimova-Dobrev	<b>Philip Chan</b>	ARASTEP A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Darolutamide Plus Androgen Deprivation Therapy (ADT) Compared With Placebo Plus ADT in Patients With High-risk Biochemical Recurrence (BCR) of Prostate Cancer	3	0
Shankar Siva	<b>Charles Lin</b>	DECREASE TROG 19.06 Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer detected by PSMA	2	1
Jarad Martin	<b>Charles Lin, Philip Chan, Robyn Cheuk, Rachel Effene, Michelle Grogan, Gary Pratt</b>	NINJA TROG 18.01 Novel Integration of New prostate radiation schedules with adjuvant Androgen deprivation	2	13
Fiona Day Jarad Martin	<b>Melissa Eastgate, Samantha Barbour</b>	PALEO Phase II clinical trial of chemoradioimmunotherapy for the ALleviation of oEsophageal cancer complications	2	0
Eric Hau	Catherine Bettington	TROG 20.01 A phase II study of platinum and etoposide chemotherapy, durvalumab with thoracic radiotherapy in the first line treatment of patients with extensive-stage small-cell lung cancer (CHEST RT)	3	0
Andrew Scott, Eng-Siew Koh	<b>Benjamin Chua</b>	TROG 18.06 Prospective, multicentre trial evaluating FET-PET in Glioblastoma (FIG)	2	12
Alison Brand	<b>Philip Chan</b>	A phase II pilot study of the use of vaginal oestriol to prevent vaginal stenosis in patients treated with radiotherapy for gynaecological, rectal and anal malignancies (VESPA)	3	5
Christopher Sweeney, Tamim Niazi	<b>Philip Chan</b>	DASL-HiCaP: Darolutamide Augments Standard Therapy for Localized High-Risk Cancer of the Prostate (ANZUP1801). A randomized phase 3 trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in high risk, clinically localized prostate cancer	3	29
Danny Rischin	<b>Charles Lin</b>	A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo after Surgery and Radiation Therapy in Patients with High-Risk Cutaneous Squamous Cell Carcinoma (C-POST)	3	6
Stephen Ackland	<b>Mathew Burge (CSS MO), Graeme Dickie</b>	A randomised, placebo-controlled phase II trial of simvastatin in addition to standard chemotherapy and radiation in preoperative treatment for rectal cancer (SPAR)	2	10

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited
Sherene Loi	<b>Robyn Cheuk, Michelle Grogan</b>	TROG 17.05 A randomised phase II trial comparing the efficacy of single fraction or multi-fraction SABR (Stereotactic ablative body radiotherapy) with Atezolizumab in patients with advanced Triple negative breast Cancer (AZTEC)	2	5
Michael Jenkinson	<b>Catherine Bettington</b>	TROG 15.02 Radiation versus Observation following surgical resection of Atypical Meningioma: a randomised controlled trial (ROAM)	2	2
Vincent Grégoire	<b>Lizbeth Kenny</b>	TROG 14.03 (EORTC-1219-ROG-HNCG) A blind randomized multicenter study of accelerated fractionated chemo-radiotherapy with or without the hypoxic cell radiosensitizer nimorazole (Nimoral), using a 15 gene signature for hypoxia in the treatment of squamous cell carcinoma of the head and neck	2	5
Danny Rischin	<b>Lizbeth Kenny</b>	TROG 12.01 A randomised trial of Weekly Cetuximab And Radiation Versus Weekly Cisplatin and Radiation in Good Prognosis Locoregionally Advanced HPV-Associated Oropharyngeal Squamous Cell Carcinoma	2	52
Chamindie Punyadeera	<b>Lizbeth Kenny</b>	A simple saliva test to diagnose head and neck cancer at an early stage - head and neck cancer detection is a spitting distance away	3	316
Rajiv Khanna	<b>Lizbeth Kenny</b>	P2191 Development of an Adoptive T Cell Therapy for HPV-Associated Malignancies	3	59
Boon Chua	<b>Lizbeth Kenny</b>	TROG 07.01 A randomised phase III study of radiation doses and fractionation schedules in non-low risk ductal carcinoma in situ (DCIS) of the breast	3	3
David Pryor	<b>Charles Lin</b>	TROG 16.03: A multi stage multi centre international randomised trial of Conventional care Or Radioablation (stereotactic body radiotherapy) for Extra-cranial oligometastatic disease in lung, breast and prostate cancer (CORE)	2	2
Shankar Siva	<b>Charles Lin</b>	TROG 15.03 Focal Ablative STereotactic RADiosurgery for Cancers of the Kidney - A Phase II Clinical Trial (FASTRACK II)	2	1
Maria Pearce	<b>Charles Lin</b>	TROG 08.03 Radiotherapy Adjuvant versus Early Salvage. A phase III multi-centre randomised trial comparing adjuvant radiotherapy (RT) with early salvage RT in patients with positive margins or extraprostatic disease following radical prostatectomy (RAVES)	2	4
Scott Williams, Paul Nguyen	<b>Philip Chan</b>	Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised, prostate cancer: ENZARAD	3	10
Peter Graham	<b>Robyn Cheuk</b>	TROG 08.06 A randomised comparison of anastrozole commenced before and continued during adjuvant radiotherapy for breast cancer versus anastrozole and subsequent anti-oestrogen therapy delayed until after radiotherapy. (STARS - Study of Anastrozole and Radiotherapy Sequencing)	2	75
Katie McMahon	Briley Devenport, Cathy Hargrave, <b>Kate Stewart</b> , Julie Burbery	The feasibility of utilising total body photography in superficial radiation therapy to assist in target volume definition planning and documentation.	3	N/A

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited
Crispen Chamunyonga	Cathy Hargrave, Kerrie Mengersen, <b>Kate Stewart</b> , <b>Gregory Rattray</b>	Development of a framework for systematic contour evaluation in radiation therapy	4	N/A

## Publications

### Authors

Investigator	ORCID ID	Investigator	ORCID ID
Catherine Bettington	0000-0002-8227-6320	Robyn Cheuk	0000-0001-9516-5526
Naasiha Cassim	0000-0002-8671-5909	Benjamin Chua	0000-0002-0377-9844
Philip Chan	0000-0002-6596-5570	Scott Crowe	0000-0001-7028-6452
Tanya Kairn	0000-0002-2136-6138	Rachel Effeney	0000-0002-6684-2601
Lizbeth Kenny	0000-0002-7556-0542	Kirby Francis	0000-0002-4285-1255
Craig Lancaster	0000-0002-8797-9586	Sarah Maxwell	0000-0003-4817-4256
Charles Lin	0000-0001-5589-4775	Samuel Peet	0000-0003-4817-4256
Kate Stewart	0000-0001-8676-6565	Tania Poroa	0000-0002-8636-5793
Rachael Wilks	0000-0002-2110-9676	Gary Pratt	0000-0001-5296-3990
Liting (Nancy) Yu	0000-0002-1264-9996		

## Publications in 2024

Journal Articles (RBWH staff or consumers in bold)

Adam A, **Kenny L**. Interventional Radiology Should Establish Its Own Identity it Should be a Primary Specialty Separate from Diagnostic Radiology. Cardiovasc Intervent Radiol. 2024 Mar;47(3):287-290. doi: 10.1007/s00270-023-03643-3. Epub 2024 Jan

Aly F, Bucknell N, **Kenny L**, Hegi-Johnson F. Part-Time Training: Leveling the Playing Field in Academic Oncology. Int J Radiat Oncol Biol Phys. 2024 Apr 19:S0360-3016(24)00504-2. doi: 10.1016/j.ijrobp.2024.04.005. Online ahead of print.PMID: 38642808

Balakittnen J, Ekanayake Weeramange C, Wallace DF, Duijf PHG, Cristino AS, Hartel G, Barrero RA, Taheri T, **Kenny L**, Vasani S, Batstone M, Breik O, Punyadeera C. A novel saliva-based miRNA profile to diagnose and predict oral cancer. International Journal of Oral Science, Feb 2024. doi.org/10.1038/s41368-023-00273-w

Barry N, Koh ES, Ebert MA, Moore A, Francis RJ, Rowshanfarzad P, Hassan GM, Ng SP, Back M, **Chua B**, Pinkham MB, Pullar A, Phillips C, Sia J, Gorayski P, Le H, Gill S, Croker J, Bucknell N, **Bettington C**, Syed F, Jung K, Chang J, Bece A, Clark C, Wada M, Cook O, Whitehead A, Rossi A, Grose A, Scott AM. [18]F-fluoroethyl-L-tyrosine positron emission tomography for radiotherapy target delineation: Results from a Radiation Oncology credentialing program. Phys Imaging Radiat Oncol. 2024 Mar 13;30:100568. doi: 10.1016/j.phro.2024.100568. eCollection 2024 Apr

**Brown TE**, **Byrnes A**, Chan AC, Dwyer K, Edwards A, **Blake CL**, **Banks MD**, **Hughes BGM**, **Lin CY**, **Kenny LM**, **Spurgin AL**, Bauer JD. Revalidation of Proactive Gastrostomy Tube Placement Guidelines for Head and Neck Cancer Patients Receiving Helical Intensity-Modulated Radiotherapy. Curr Oncol. 2024 Nov 6;31(11):6938-6955. doi: 10.3390/curroncol31110512.PMID: 39590143

**Carroll MA**, **Sommerville R**, Hay K, **Walker A**, **Grigg S**, **Kenny L**, **Chua B**, **Papacostas J**, **Alexander H**, **Lin C**. Survival and Patterns of Relapse of Cutaneous Squamous Cell Carcinoma With Large Nerve Perineural Spread After Skull Base Surgery and/or Radiation Therapy. Pract Radiat Oncol. 2024 Oct 26:S1879-8500(24)00269-8. doi: 10.1016/j.prro.2024.09.007. Online ahead of print.PMID: 39466219

**Croisier E**, **Brown T**, **Grigg A**, **Chan P**, Bauer J. Dietary counselling to increase soluble fibre in patients with gynaecological cancers undergoing pelvic radiotherapy: A feasibility study. J Hum Nutr Diet. 2025 Feb;38(1):e13402. doi: 10.1111/jhn.13402.PMID: 39587777

Ekanayake Weeramange C, Tang KD, Irwin D, Hartel G, Langton-Lockton J, Ladwa R, **Kenny L**, Taheri T, Whitfield B, Vasani S, Punyadeera C. Human papillomavirus (HPV) DNA methylation changes in HPV-associated head and neck cancer. Carcinogenesis. 2024 Mar 11;45(3):140-148. doi: 10.1093/carcin/bgae001

## Journal Articles (RBWH staff or consumers in bold)

**Mackenzie P**, Vajdic C, Delaney G, Comans T, Agar M, Gabriel G, Barton M. Assessing a Suitable Radiotherapy Utilisation Benchmark for Older Patients With Head and Neck Cancer. Clin Oncol (R Coll Radiol). 2024 Oct;36(10):e381-e387. doi: 10.1016/j.clon.2024.05.014. Epub 2024 May 31

**McCoola B, Outhwaite JA, Lathouras M**, Pelecanos A, **Blyth J**, Carter A, Hastings Y, **Rattray G, Cheuk R**. An evaluation of the use and efficacy of behavioural therapy when treating paediatric patients with radiation therapy. J Med Radiat Sci. 2023 Dec;70(4):436-443. doi: 10.1002/jmrs.705. Epub 2023 Jul 13

Mehawed G, **Roberts MJ**, Bugeja J, Dowling J, **Stewart K, Gunasena R**, Malczewski F, Rukin NJ, Murray R. A Pilot Study of PSMA PET/CT and MRI Fusion for Prostate Cancer: Software to Replace PET/MRI Hardware. J Clin Med. 2024 Dec 4;13(23):7384. doi: 10.3390/jcm13237384. PMID: 39685842

Porceddu SV, Negrello T, Rawson N, Dunn N, Batstone M, Collins M, Douthwaite S, **Hughes BG, Kenny L**, Ladwa R, Panizza B, Cossio D. Human papillomavirus associated oropharyngeal cancer now the most common mucosal head and neck cancer in Queensland. J Med Imaging Radiat Oncol. 2024 Apr 23. doi: 10.1111/1754-9485.13643. Online ahead of print. PMID: 38654618

Siva S, Bressel M, Sidhom M, Sridharan S, Vanneste BGL, Davey R, Montgomery R, Ruben J, Foroudi F, Higgs B, **Lin C**, Raman A, Hardcastle N, Hofman MS, De Abreu Lourenco R, Shaw M, Mancuso P, Moon D, Wong LM, Lawrentschuk N, Wood S, Brook NR, Kron T, Martin J, Pryor D; Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial. Lancet Oncol. 2024 Mar;25(3):308-316. doi: 10.1016/S1470-2045(24)00020-2

A, Ekanayake Weeramange c, Vasani S, **Kenny L**, Knowland E, Seneviratne J, Punyadeera C. Surveillance of human papillomavirus through salivary diagnostics-A roadmap to early detection of oropharyngeal cancer men. Tumour Virus Research, Elsevier Journal, Mar 2024. doi.org/10.1016/j.tvr.2024.200278

Wong M, Vasani S, Breik O, Zhang X, **Kenny L**, Punyadeera C. The potential of hydrogel-free tumoroids in head and neck squamous cell carcinoma. Cancer Med. 2024 Aug;13(16):e70129. doi: 10.1002/cam4.70129. PMID: 39169896; PMCID: PMC11339536

Wong M, Vasani S, Breik O, Zhang X, **Kenny L**, Punyadeera C. The potential of hydrogel-free tumoroids in head and neck squamous cell carcinoma. Cancer Med. 2024 Aug;13(16):e70129. doi: 10.1002/cam4.70129. PMID: 39169896; PMCID: PMC11339536

Wong M, Vasani S, Breik O, Zhang X, **Kenny L**, Punyadeera C. The potential of hydrogel-free tumoroids in head and neck squamous cell carcinoma. Cancer Med. 2024 Aug;13(16):e70129. doi: 10.1002/cam4.70129. PMID: 39169896; PMCID: PMC11339536

Wong M, Vasani S, Breik O, Zhang X, **Kenny L**, Punyadeera C. The potential of hydrogel-free tumoroids in head and neck squamous cell carcinoma. Cancer Med. 2024 Aug;13(16):e70129. doi: 10.1002/cam4.70129. PMID: 39169896; PMCID: PMC11339536

Zhang X, Weeramange CE, **Hughes BGM**, Vasani S, Liu ZY, Warkiani M, Hartel G, Ladwa R, Thiery JP, **Kenny L**, Breik O, Punyadeera C. Circulating tumour cells predict recurrences and survival in head and neck squamous cell carcinoma patients. Cell Mol Life Sci. 2024 May 23;81(1):233. doi: 10.1007/s00018-024-05269-1. PMID: 38780775.

## Keynote or Plenary Lectures given in 2024

Date	Title
2/12/2024	<b>Kenny L</b> . How Quality of Care Is Assured in Radiation Oncology and Why This Is Also Applicable to IO   M6-RCP22B. Radiological Society of North America ASM, Chicago
31/10/2024	<b>Kairn T</b> . Motion Management. National Particle Therapy Symposium, Melbourne, Australia. 31 Oct – 1 Nov 2024
19/10/2024	<b>Mackenzie P</b> . A Model in Radiation Oncology. [Oral Presentation]. International Society of Geriatric Oncology (SIOG) Annual Conference, Montreal, Canada
13/11/2024	<b>Mackenzie P</b> . Treleaven E. Co-Chair: Geriatric Oncology Session, Clinical Oncology Society of Australia (COSA) Annual Scientific Meeting, Gold Coast, Queensland, Australia. 13- 15 November 2024
28/5/2024	<b>Kenny L</b> . HPV and Head and Neck Cancer. The Australian Prosthodontic Society QLD Brisbane
1/5/2024	<b>Kenny L</b> . Planning, Delivery and Verification in Radiation Oncology in Radiation Oncology European Congress of Interventional Oncology. Mallorca Spain
1/5/2024	<b>Kenny L</b> . Foundations Course in Oncology – How to Maximise Multidisciplinary Team Care. European Congress of Interventional Oncology. Mallorca Spain
15/3/2024	<b>Kenny L</b> . National Quality Management Committee Update, National Accreditation Standards (NAS) Discussion on Future Management. BreastScreen Australia Conference, Canberra





**Associate Professor David Wyld**  
**Deputy Director of Clinical Research CCS**

2024 was another busy year for the Department of Medical Oncology's research unit. The unit undertakes research at both Royal Brisbane and Women's Hospital and The Prince Charles Hospital, as well as at the North Lakes Cancer Centre, and with regional sites via the teletrials research model.

2024 was a year of significant change, with a move of the CCS Research unit to block 7 after 15 years in Building 34. That the whole unit could prepare and then move without any significant impact on current clinical trials and other research programs is a great credit to all those involved.

The Medical Oncology research program remained very active throughout 2024, undertaking a large number of clinical trials and research studies. In addition, the department continues to undertake research with a wide variety of collaborators.

I would like to highlight several of the departments 2024 achievements.

- ❖ The Medical Oncology Department and RBWH Nuclear Medicine Department, partnering with an Australian clinical stage radiopharmaceutical company, commenced a first in human Phase I dose escalation study of a novel targeted alpha therapy in metastatic prostate cancer. That such a study is being undertaken at RBWH is a credit to all involved. This follows the successful completion of a number of previous therapeutic radioisotope studies undertaken in both prostate cancer and neuroendocrine tumours over several years.
- ❖ Commencement of the GBM AGILE study at RBWH – one of 6 sites Australian trial sites, and the only Qld site. GBM AGILE is the world's first adaptive clinical trial platform with a unique approach to the traditional clinical trial which will enable faster and cost-effective development of new treatments versus conventional trials for glioblastoma multiforme and is sponsored in Australia by the Cure Brain Cancer charity.
- ❖ The STOPNET trial, a clinical trial in patients with metastatic neuroendocrine tumours undergoing therapeutic radioisotope therapy. This study was devised by and is being led by principal investigator A/Prof Matthew Burge, with RBWH the lead study site, funded in Australia by a successful MRFF Grant application in 2023. The trial in Qld is being run as a teletrial, allowing recruitment of patients from across the state, with follow up able to be undertaking in patients' closest cancer service. The study is being conducted through AGITG in the 6 major Australian Neuroendocrine treatment centres, as well as in a number of Canadian sites via the CCTG research group.
- ❖ The unit continues to undertake research with a wide variety of collaborators both locally and from around the country. This can be demonstrated by:
  - In collaboration with researchers at QIMR, the commencement of the PaxPlus-ABC (KZA-0084-ABC001) clinical trial, a phase 1b study to evaluate the safety, tolerability, and clinical activity of combining paxalisib with standard therapy in patients with advanced breast cancer.
  - The number of collaborative research activities involving our group as listed in the report below – these include multiple Australasian Cancer Collaborative trials groups, several different academic institutions and research institutes, as well as colleagues in other clinical services.
  - The number of collaborative research grants held by members of our department in conjunction with research collaborators around the country, including 15 NHMRC/ MRFF grants.

Research publications. Over 40 manuscripts were published by departmental staff in 2024, including a number in high impact journals such as The Journal of Clinical Oncology, Journal of Neuro-Oncology, The Lancet Oncology, European Journal of Cancer and Gynecologic Oncology.

## Research Grants

Investigator Names (RBWH staff in bold)	RBWH Departments / Research Groups	Research Project Title	Granting Body	Total Awarded (whole all years)	Length of Awards in years and years active
<b>Medical Oncology Clinical Trials Unit</b>	CCS Medical Oncology	CCQ- Clinical Trials Data Management Grant. Medical Oncology	Cancer Council Queensland	\$97,000	1 year, 2024
<b>Brett Hughes</b>	CCS Medical Oncology	Understanding how immunotherapy for non- small cell lung cancer alters the immune environment to achieve better outcomes	IMPACT Philanthropy Application Program	\$56,040	1 year, 2023-2024
Kulasinghe A, <b>Hughes BGM</b>	CCS Medical Oncology	Developing a multi-omic, high-dimensional assessment of head and neck cancer	Garnett Passe and Rodney Williams Memorial Foundation	\$500,000	2 years, 2023-2024
Arutha Kulasinghe, Rahul Ladwa, Ken O'Byrne, Scott Coman, Ben Wallwork, Gabrielle Belz, Kirsten Russell, Duncan Lambie, <b>Brett Hughes</b>	CCS Medical Oncology	Astronomy meets pathology: an interdisciplinary effort to develop a head and neck cancer cellular atlas for immunotherapy	MSH SERTA	\$100,000	3 years, 2022-2024
Niall Tebbutt, Jeanne Tie, Chris Karapetis, Steve Ackland, Connie Diakos, <b>Matthew Burge</b> , Naureen Starling, Tony Dhillon, Christine Bishop, David Church, David Lau, Kate Mahon, Sonia Yip, Sophia Frentzas, Yoko Tomita, Kate Wilson	CCS Medical Oncology	POLEM Trial, a phase III randomised study of Avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III dMMR or POLE exonuclease domain mutant colon cancer	MRFF International Clinical Trials Collaborations Grant	\$981,313	5 years, 2020-2024
Paul Thomas, John Hooper, Trent Munro, <b>David Wyld</b> , Luke Perrin, Rohan Lourie, Stephen Rose, Simon Puttick	CCS Medical Oncology, Nuclear Medicine	A new radio-imaging agent to guide targeted therapy for epithelial ovarian cancer	NHMRC MRFF – Emerging Priorities and Consumer Driven Research - 2019 Ovarian Cancer Research Grant. (APP1199422)	\$1,893,306	5 years, 2020-2024
Sunil Lakhani, Amy Reed, Christopher Pyke, Cameron Snell, Nicole McCarthy, Ken O'Byrne, Valentine Hyland, Owen Ung, Natasha Woodward, Euan Walpole, Peter Simpson, Stephen Rose, Fares Al-Ejeh, <b>Po-Ling Ingilis</b> , Ben Green	CCS Medical Oncology	Whole Genome Sequencing in high-risk breast cancer patients	MRFF Genomics Health Futures Mission	\$2,800,000	5 years, 2020-2024
Punyadeera C, Kenny L, Sriram S, <b>Hughes B</b> , Leo P, Papautsky I	CCS Medical Oncology	Multi-analyte liquid biopsy-based biomarkers for oropharyngeal cancer	NHMRC (National Health and Medical Research Council)	\$763,417	4 years, 2022-2025

Investigator Names (RBWH staff in bold)	RBWH Departments / Research Groups	Research Project Title	Granting Body	Total Awarded (whole all years)	Length of Awards in years and years active
Vanessa Beesley, Rachel Neale, Jane Turner, Patsy Yates, <b>David Wyld</b> , Raymond Chan, Louisa Gordon	CCS Medical Oncology	PRoCESS: Pancreatic cancer Relatives Counselling and Education Support Service trial. Assessing the effect of nurse-led counselling, compared with information alone, on participant-reported outcomes and use of medical services	NHMRC MRFF – Research Grant (APP1200326)	\$801,229	5 years, 2020-2025
K Fong, I Yang, H Marshall, R Bowman, R O'Rourke, P Valery, E Stone, R Manser, K Canfell, M Weber, G Garvey, S Lam, M Tammemagi, S Sabesan, Z Otty, F Brims, A McWilliams, B Page, J De Laat, S Hambleton, G Pratt, P Chan, M Windsor, R Naidoo, <b>B Hughes, Z Lwin</b> , K Hopcraft, M Toombs, P Fogart, P Tobias, B Bartholmai, F Maldonado, F Martignano, S Conticello, P Grogan, L Passmore, A Dent, G Olive, B Parris, H O'Farrell, K Chee	CCS Medical Oncology, CCS Radiation Oncology	Improving outcomes for people with and at risk of lung cancer	Australian Cancer Research Foundation	\$2,000,000	4 years, 2022-2025
J Zalcborg, K Sjoquist, N Tebbutt, D Yip, J Desai, T Price, L Lipton, C Diakos, S Ananda, C Kin Law, C Bishop, S Ackland, S Yip, R Morton, <b>D Wyld</b> , D Goldstein, J Mumford	CCS Medical Oncology	SSG XXII: International randomised phase III multicenter study of 3 v 5 years of adjuvant imatinib as treatment of patients with operable GIST with high risk for recurrence	NHMRC MRFF 2020 International Clinical Trial Collaborations	\$1,036,125	6 years, 2021-2026
Raymond Chan, Jon Emery, Michael Jefford, Nicolas Hart, Gillian Harvey, <b>David Wyld</b> (CI F), David Chan, Michelle Miller, Sanjeewa Kularatna, Lee Jones	CCS Medical Oncology	Implementing a Nurse-Enabled, Shared-Care Model to Address Unmet Needs of People with Neuroendocrine Tumours: the AUS-NET Trial	NHMRC 2021 MRFF Rare Cancers, Rare Diseases and Unmet Need	\$2,374,220	5 years, 2022-2026
Penelope Schofield, Linda Mileschkin, Anna Ugalde, Richard Tothill, Stephen Quinn, Hui-li Wong, Owen Prall, Catherine Mitchell, Nilmini Wickramasinghe, Clare Fedele, Colin Wood, Louisa Gordon, Christopher Steer, Rachel Wong, Mark Shackleton, Louise Nott, Shamsudheen Padinharakan, Zee Wan Wong, <b>Anna Kuchel</b>	CCS Medical Oncology	Solving Unknown Primary cancer Earlier Diagnosis (SUPER-ED): A stepped wedge cluster randomised controlled trial implementing a new model of care to support earlier diagnosis	MRFF (Medical Research Future Fund)	\$2,400,000	5 years, 2022-2026

Investigator Names (RBWH staff in bold)	RBWH Departments / Research Groups	Research Project Title	Granting Body	Total Awarded (whole all years)	Length of Awards in years and years active
Penny Webb, Nina Na, Susan Jordan, Karen Canfell, <b>Jeffrey Goh</b> , Yoland Antill, Ming Yin Lin, Paul Cohen, Felicia Roncolato, Megan Smith	CCS Medical Oncology	Investigate variation and inequality in care and survival to Improve outcomes for women with cervical, uterine, vaginal and vulvar cancer in Australia	Cancer Australia	\$599,307	4 years, 2023-2026
Sudha Rao, Corey Smith, Gunter Hartel, Maciej Trzaskowski, <b>Zarnie Lwin</b> , Jane Dahlstrom, <b>Melissa Eastgate</b> , Vladimir Andelkovic, Sayed Ali	CCS Medical Oncology	Epigenetic checkpoint blockade: a new approach to enhance immune-mediated control	NHMRC Ideas Grant 2022	\$1,280,076	5 years, 2023-2027
Vicki Whitehall, Eric Shifrut, Ann-Marie Patch, Catherine Bond, Bianca Nowlan, Jennifer Borowsky, Juan Dubrot, <b>Matthew Burge</b> , David Clark	CCS Medical Oncology	New Approaches for Sensitising Metastatic Colorectal Cancer to Immunotherapy	NHMRC Ideas Grant 2022	\$1,419,345	5 years, 2023-2027
R Jeffree, B Day, C Gedye, ES Koh, R Leonard, HW Sim, W Varikatt, D Hansen, D Cossio, R Harrup, H Gan, J Zalcberg, T O'Brien, K Drummond, M Pinkham, R Ormsby, G Gomez, K Alexander, M Buckland, N Good, M Sachchithananthan, A Scott, J Whittle, D Ziegler, C Vajdic, W Lipworth, J Dickinson, L Quinn, J Aitken, <b>Z Lwin</b> , JHansford, A Yule, M Agar, G Kichenadasse, D Truran, G Francois, W Chin, B Kong, J Gabriel, A Lee, <b>C Turner</b> , S Evans, W Ng, R Sullivan, S Pitson, A Nguyen	CCS Medical Oncology	Australian Brain Cancer Research Infrastructure Grant: Supporting brain cancer care with an integrated network of platforms	MRFF (Medical Research Future Fund)	\$5,991,219	5 years, 2023-2027
Arutha Kulasinghe, Mark Adams, Gabrielle Belz, Dharmesh Bhuv, Charles Bidgood, Sophie Curio, Melissa Davis, Jennifer Gunter, Angela Huang, <b>Brett Hughes</b> , Ning Liu, Kenneth O'Byrne, Amelia Parker, Chin Wee Tan, Haitham Tuffaha	CCS Medical Oncology	METASPIAL Study: Metabolic Spatial Analysis of Lung Cancer Study	MRFF (Medical Research Future Fund)	\$999,825	4 years, 2024-2028
<b>Matthew Burge</b> , <b>David Wyld</b> , David Pattison, Lorraine Chantrill, Michael Michael, Timothy Price, David Ransom, David Chan, Vicki Whitehall, Richard De Abreu Lourenço, Carrie-Anne Ng	CCS Medical Oncology	Cessation of Somatostatin Analogues after Peptide radionuclide Therapy in non-functioning mid-gut Neuroendocrine tumours (STOPNET)	MRFF (Medical Research Future Fund)	\$1,285,404	5 years, 2024-2029

## RBWH Department / Research Group Lead Research Activity

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited
<b>Matthew Burge</b> , Victoria Whitehall	<b>David Wyld, Melissa Eastgate</b> , Alison Hadley, <b>Brett Hughes</b> , <b>Po-ling Inglis, Zarnie Lwin, Jeff Goh, Darshit Thaker</b> , Bahram Forouzesh, Sudhakar Vemula, Elizabeth Ahern, Jennifer Borowsky	The Royal Brisbane and Prince Charles Hospital metastatic Colorectal Cancer database: A prospective observational cohort study examining clinical and molecular biomarkers	3	373
<b>Melissa Eastgate</b>	Michelle Wykes, Rebecca Faleiro, Deshapriya Karunarathne	INVITE: In vitro testing of a novel immunotherapy for advanced cancer	3	60
<b>Melissa Eastgate</b>	Michele Teng, Bill Dougall, Margaret Cummings, Rosalind Jeffree, Shu Lee, <b>Anna Kuchel</b> , Elizabeth Ahern	MISTY trial (Melanoma Immunotherapy Stratification and Treatment Sensitivity) Cutaneous Malignancies Group	3	5
<b>Melissa Eastgate</b>	Sudha Rao, <b>David Wyld, Kathy You</b> , Robert McCuaig, <b>Haidar Al-Saig, Harry Gasper, Jeff Goh, Brett Hughes, Po Inglis, Anna Kuchel, Zarnie Lwin, Darshit Thaker</b>	Immunotherapy STARS (Stratifying Therapeutic Resistance and Sensitivity) - immunotherapy treatment cohort	3	85
<b>Chun Loo Gan</b>	<b>Haidar Al-Saig</b> , Zi Long Chow, Ciara Conduit, Nattakorn Dhiantravan, Craig Gedye, <b>Jeffrey Goh</b> , Laurence Krieger, <b>Anna Kuchel</b> , Niara Oliveira, Shivanshan Pathmanathan, David Pattison, Steven Smith, <b>Aneta Suder</b> , Andrew Weickhardt, <b>Yong Yeung</b>	PREDICT-RCC: PREDICTing treatment response to first-line immunotherapy-based combinations with PSMA and FDG PET in advanced clear cell Renal Cell Carcinoma	3	1
<b>Mark Nalder</b>	<b>Matthew Burge, David Wyld, Melissa Eastgate</b> , Sarah Steinke	Pre-treatment dihydropyrimidine dehydrogenase (DPYD) genotyping to individualise fluoropyrimidine-based chemotherapy: An evaluation of clinical implementation in a tertiary cancer centre.	3	335 In follow-up
<b>Brett Hughes</b>	Elizabeth Ahern, Bill Dougall	Pharmacodynamics of Pre-Operative PD1 Checkpoint Blockade and Receptor Activator of NF-κB Ligand (RANKL) Inhibition in Non-Small Cell Lung Cancer (NSCLC) – a phase 1B/2 trial. POPCORN	3	10 In follow-up
<b>Kyung You</b>	<b>Zarnie Lwin</b> , Natasha Roberts	Multifactorial determinants that influence clinical trial participation by cancer patients in Australia.	4	N/A
<b>Brett Hughes</b>	<b>Cassie Turner</b>	Outcomes for patients with radioactive iodine-refractory thyroid cancer treated within the Royal Brisbane and Women's Hospital	4	N/A
<b>Melissa Eastgate</b>	Geoffrey Bryant, <b>Mathew Burge, Darshit Thaker, David Wyld</b> , Cameron Curley, Michele Grogan, Jemma Byth	Cancer patient reported outcomes: putting theory into practice	3	297 In follow-up
<b>Melissa Eastgate</b> , Elizabeth Ahern, <b>Anna Kuchel</b>	Ailin Lepetier, Jason Madore	Multiplex immunofluorescence assessment of melanoma biopsies and response to immunotherapy	4	N/A
<b>Brett Hughes</b> , Elizabeth Ahern	Martin Batstone, Bill Dougall	Immune Biomarker Evaluation in Oral Mucosal Squamous Cell Carcinoma: a prospective tissue collection	4	N/A



Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited
<b>Melissa Eastgate</b>	Rosalind Jeffrey (Neurosurgery), Margaret Cummings (Pathology), Elizabeth Ahern, <b>Anna Kuchel</b> , Shu Lee (Medical Oncology Ipswich), Michael Colditz (Neurosurgery)	Clinicopathologic feature predicting survival after brain metastasectomy in melanoma	4	N/A
Wessling C, Gavin N	Russell E, Glynn T, <b>Eastgate M</b> , Hajkowicz K, Klages P, Leutenegger J, Sandler C, Clark B, Hutchinson E, Sutherland A,	A Randomised Controlled Trial exploring the administration of intravenous antibiotics and fluids via intravenous pole and pump versus portable CADD pump to improve mobility in patients diagnosed with cancer (The Active Trial)	3	Not available

### Collaborative Research Activity Involving RBWH Department / Research Group

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited
Australasian Gastrointestinal Trials Group	<b>Matthew Burge</b> (Cancer Care Services)	STOPNET: A randomised study of cessation of somatostatin analogues after Peptide Receptor Radionuclide Therapy in Mid-Gut Neuroendocrine tumours	3	3
Australasian Gastrointestinal Trials Group	<b>Matthew Burge</b> (Cancer Care Services)	INTEGRATE II Randomised Phase III Double Blind Placebo Controlled Study of regorafenib in Refractory Advanced GastroOesophageal Cancer	3	12 In follow-up
Australasian Gastrointestinal Trials Group	<b>Matthew Burge</b> (Cancer Care Services)	ACTICCA-1 study: Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Observation After Curative Intent Resection of Cholangiocarcinoma and Muscle Invasive Gall Bladder Carcinoma (ACTICCA-1 Trial)	3	9 In follow-up
Australasian Gastrointestinal Trials Group	<b>Matthew Burge</b> (Cancer Care Services)	ASCEND: Randomized, phase 2 study of gemcitabine and nab-paclitaxel with CEND-1 or placebo in patients with untreated metastatic pancreatic ductal adenocarcinoma.	3	9 In follow-up
Australasian Gastrointestinal Trials Group intestinal Trials Group	<b>Melissa Eastgate</b> (Cancer Care Services)	ASCOLT: Aspirin for Dukes C and high risk Dukes B Colorectal Cancers: An international, multi-centre, double blind, randomised placebo controlled Phase III trial (AGITG)	3	9 In follow-up
Australasian Gastrointestinal Trials Group	<b>Matthew Burge</b> (Cancer Care Services)	MONARCC: A randomised phase 2 study of Panitumumab monotherapy versus fluoropyrimidine and bevacizumab as first line therapy for RAS wild type metastatic colorectal cancer	3	10 In follow-up
Breast Cancer Trials	<b>Po-Ling Inglis</b> (Cancer Care Services)	BRCA-P: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Phase 3 Study to determine the Preventive Effect of Denosumab on Breast Cancer in Women carrying a BRCA1 Germline Mutation	3	4 In follow-up
Breast Cancer Trials	<b>Po-Ling Inglis</b> (Cancer Care Services)	FINER: A double-blind placebo controlled randomized Phase III trial of fulvestrant and ipatasertib as treatment for advanced HER-2 negative and estrogen receptor positive (ER+) breast cancer following progression on first line CDK 4/6 inhibitor and aromatase inhibitor	3	3 In follow-up

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited
Australia New Zealand Breast Cancer Trials Group	<b>Michelle Nottage</b> (Cancer Care Services)	PALLAS: PALbociclib CoLLaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer	3	20 In follow-up
Australia New Zealand Breast Cancer Trials Group	<b>Po-Ling Inglis</b> (Cancer Care Services)	Penelope B: Phase III study evaluating palbociclib (PD-0332991), a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor in patients with hormone-receptor-positive, HER2-normal primary breast cancer with high relapse risk after neoadjuvant chemotherapy	3	1 In follow-up
Australia New Zealand Breast Cancer Trials Group/Breast International Group	<b>Michelle Nottage</b> (Cancer Care Services)	TEXT-Bone: A substudy of the TEXT trial to evaluate serial bone markers for bone remodeling, serial growth factors, and bone mineral density	3	5 In follow-up
Australia New Zealand Breast Cancer Trials Group/Breast International Group	<b>Michelle Nottage</b> (Cancer Care Services)	TEXT: A Phase III Trial Evaluating the Role of Exemestane plus GnRH analogue as Adjuvant Therapy for premenopausal women with endocrine responsive breast cancer	3	11 In follow-up
Australia New Zealand Gynaecological Oncology Group	<b>Jeffrey Goh</b> (Cancer Care Services)	ADELE: Adjuvant Tislelizumab plus chemotherapy after post-operative pelvic chemoradiation in high-risk endometrial cancer	3	6
Australia New Zealand Gynaecological Oncology Group	<b>Jeffrey Goh</b> (Cancer Care Services)	EPOCH: Eribulin and Pembrolizumab in Ovarian/uterine Carcinosarcoma and sarcoma: A Phase 2 study of the single agent microtubule inhibitor, Eribulin or of Eribulin in combination with the PD-1 inhibitor, Pembrolizumab, in relapsed ovarian/fallopian tube carcinosarcoma (OCS), uterine carcinosarcoma (UCS), angiosarcoma and liposarcoma	3	1
Australia New Zealand Gynaecological Oncology Group	<b>Jeffrey Goh</b> (Cancer Care Services)	PARAGON-II: Phase II basket study of an ARomatase inhibitor plus PI3KCA inhibitor or CDK4/6 inhibitor in women with hormone receptor positive recurrent/metastatic Gynaecological Neoplasms	3	15
Australia New Zealand Gynaecological Oncology Group	<b>Jeffrey Goh</b> (Cancer Care Services)	ICON 9: to assess the efficacy, safety and tolerability of maintenance cediranib in combination with olaparib therapy compared to single agent cediranib maintenance in women with relapsed platinum sensitive ovarian, fallopian tube or primary peritoneal cancer	3	3 In follow-up
Australia New Zealand Gynaecological Oncology Group	<b>Jeffrey Goh</b> (Cancer Care Services)	iPRIME: A phase II study of durvalumab and tremilumumab in combination with carboplatin and paclitaxel, as neoadjuvant treatment for newly diagnosed, advanced high grade serous ovarian cancer	3	3 In follow-up
Australia New Zealand Gynaecological Oncology Group	<b>Jeffrey Goh</b> (Cancer Care Services)	MOCCA: A Multicentre Phase II randomised trial of MEDI4736 versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinomas.	3	3 In follow-up

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited
Australia New Zealand Gynaecological Oncology Group	<b>Aneta Suder</b> (Cancer Care Services)	OUTBACK - A PHASE III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone	3	14 In follow-up
Australia and New Zealand Melanoma Trials Group	<b>Melissa Eastgate</b> (Cancer Care Services)	STOP-GAP: A randomised phase III study of duration of Anti-PD-1 therapy in metastatic melanoma	3	2 In follow-up
Australia New Zealand Urogenital and Prostate Cancer Trials Group	<b>David Wyld</b> (Cancer Care Services)	BEP: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for participants with intermediate and poor-risk advanced germ cell tumours	3	8
Australia New Zealand Urogenital and Prostate Cancer Trials Group	<b>Anna Kuchel</b> (Cancer Care Services)	CLIMATE: Assessing the Clinical utility of miR-371a-3p as a marker of residual disease in Clinical Stage 1 Testicular Germ Cell Tumour, following orchidectomy.	3	7
Australia New Zealand Urogenital and Prostate Cancer Trials Group	<b>Jeffrey Goh</b> (Cancer Care Services)	EVOLUTION: Phase II Study of Radionuclide 177Lu-PSMA Therapy versus 177Lu-PSMA in Combination with Ipilimumab and Nivolumab for Men with Metastatic Castration Resistant Prostate Cancer (mCRPC)	3	15 In follow-up
Australia New Zealand Urogenital and Prostate Cancer Trials Group	<b>Aneta Suder</b> (Cancer Care Services)	UpFront PSMA: A Randomised Phase 2 Study of Sequential 177Lu-PSMA617 and Docetaxel versus Docetaxel in Metastatic Hormone-Naïve Prostate Cancer	3	11 In follow-up
Australia New Zealand Urogenital and Prostate Cancer Trials Group	<b>Aneta Suder</b> (Cancer Care Services)	ENZAMET Trial: A randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer	3	2 In follow-up
Australia New Zealand Urogenital and Prostate Cancer Trials Group	<b>Jeffrey Goh</b> (Cancer Care Services)	ENZA-p: A phase 2 open label randomised trial of enzalutamide versus enzalutamide+ Lu PSMA 617, in the early mCRPC setting prior to chemotherapy (stratified for hormone sensitive chemo) in men at high risk of early treatment failure on enzalutamide alone. (ANZUP)	3	13 In follow-up
Australia New Zealand Urogenital and Prostate Cancer Trials Group	<b>Jeffrey Goh</b> (Cancer Care Services)	KEYPAD: Proposed phase 2 trial of pembrolizumab and denosumab in advanced clear-cell renal cell carcinoma (ccRCC) progressing after a VEGF-TKI	3	4 In follow-up
Australia New Zealand Urogenital and Prostate Cancer Trials Group	<b>Jeffrey Goh</b> (Cancer Care Services)	UNICAB: A phase II trial of single agent cabozantinib in patients with locally advanced or metastatic non-clear cell renal cell carcinoma post immunotherapy or who are unsuitable for immunotherapy	3	5 In follow-up
Australian Genomic Cancer Medicine Centre, University of Sydney	<b>Brett Hughes</b> (Cancer Care Services)	MoST 08: Molecular Screening and Therapeutics (MoST) Program Substudies 19-20 and 35-36: Single arm, open label, signal seeking, phase IIa trial of the activity of Trastuzumab emtansine (T-DM1) in patients with tumours harbouring HER2 amplifications or mutations	3	1

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited
Australian Genomic Cancer Medicine Centre, University of Sydney	<b>Brett Hughes</b> (Cancer Care Services)	MoST 12: Molecular Screening and Therapeutics (MoST) Program and ASPIRATION subprogram substudies 27 - 30: Single arm, open label, phase II trial of the activity of vemurafenib and cobimetinib in patients with advanced tumours harbouring BRAF V600 mutations detected by comprehensive genomic profiling	3	1 In follow-up
Australian Genomic Cancer Medicine Centre, University of Sydney	<b>Brett Hughes</b> (Cancer Care Services)	MoST Aspiration Framework: An observational cohort study to assess the clinical impact of comprehensive genomic profiling in metastatic lung cancer patients. A subprogram within the MoST Framework protocol	3	24 In follow-up
BioGrid Australia	<b>Jeffrey Goh</b> (Cancer Care Services)	ePAD: Analyzing Treatment Patterns and Outcomes from Real-World Patients with Castrate-Resistant Prostate Cancer (CRPC)	4	100
BioGrid Australia	<b>Matthew Burge</b> (Cancer Care Services)	TRACC: Study of Clinical Outcomes and Analysis of Bevacizumab use in Metastatic Colorectal Cancer	4	216
Canadian Cancer Trials Group	<b>Matthew Burge</b> (Cancer Care Services)	CHALLENGE: A Phase III study of the impact of a Physical Activity program on Disease-Free Survival in patients with high risk Stage II or Stage III Colon Cancer: a randomised controlled trial	3	31 In follow-up
Cooperative Trials Group for Neuro-oncology	<b>Zarnie Lwin</b> (Cancer Care Services)	LUMOS2: Low and Anaplastic Grade Glioma Umbrella Study of Molecular Guided Therapies: A phase 2, multi-centre, open-label, biomarker-directed, umbrella, clinical trial for recurrent IDH mutant, grade 2/3 glioma.	3	6
Cooperative Trials Group for Neuro-oncology	<b>Zarnie Lwin</b> (Cancer Care Services)	MAGMA Trial: The Multi-Arm Glioblastoma Australasia Trial (COGNO)	3	22 In follow-up
Cooperative Trials Group for Neuro-oncology	<b>Zarnie Lwin</b> (Cancer Care Services)	LUMOS: Low & Intermediate Grade Glioma Umbrella Study of Molecular Guided Therapies – Pilot Study. (COGNO)	3	2 In follow-up
Cooperative Trials Group for Neuro-oncology	<b>Zarnie Lwin</b> (Cancer Care Services)	NUTMEG: A Randomized Phase II Study of Nivolumab and Temozolomide vs Temozolomide in newly diagnosed Elderly Glioblastoma	3	8 In follow-up
Cooperative Trials Group for Neuro-oncology	<b>Zarnie Lwin</b> (Cancer Care Services)	VERTU: Veliparib, Radiotherapy and Temozolomide trial in Unmethylated MGMT Glioblastoma: A Randomised Phase II study of veliparib + radiotherapy (RT) with adjuvant temozolomide (TMZ) + veliparib versus standard RT + TMZ followed by TMZ in newly diagnosed glioblastoma (GBM) with unmethylated O (6)-methylguanine-DNA methyltransferase	3	25 In follow-up
Flinders University	<b>Michelle Nottage</b> (Cancer Care Services)	Finding My Way – Advanced: Can a web-based psychosocial intervention improve mental quality of life for women with metastatic breast cancer?	3	39
Melanoma and Skin Cancer Trials Limited	<b>David Wyld</b> (Cancer Care Services),	GoTHAM: A Merkel Cell Carcinoma (MCC) study testing the immunotherapy drug Avelumab in combination with either radionuclide therapy or external beam radiotherapy	3	2
Melanoma and Skin Cancer Trials Limited	<b>Melissa Eastgate</b> (Cancer Care Services)	I-MAT: - A randomised, placebo-controlled, phase II trial of adjuvant Avelumab in patients with stage I-III Merkel cell carcinoma	3	5 In follow-up

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited
Melanoma and Skin Cancer Trials Limited	<b>Melissa Eastgate</b> (Cancer Care Services)	CHARLI: A Phase Ib/II Trial of Ipilimumab-Nivolumab-Denosumab and Nivolumab-Denosumab in Patients with Unresectable Stage III and IV Melanoma	3	5 In follow-up
Metro South HHS	<b>Brett Hughes</b> (Cancer Care Services)	DESQUAMATE: A phase 2 study of de-escalation in resectable, locally advanced cutaneous squamous cell carcinoma with the use of neoadjuvant Pembrolizumab	3	4 In follow-up
NeuroEndocrine Cancer Australia	<b>David Wyld</b> (Cancer Care Services)	An Observational, Multi-centre, Non-Interventional Programme to Register Patients Diagnosed With Neuroendocrine Neoplasms (NENs) and Monitor their Patterns of Care in Australian Hospitals. PLANET Registry	4	12
Olivia Newton-John Cancer Research Institute	<b>Chun Loo Gan</b> (Cancer Care Services)	PIRC PSMA PET: 68Ga-PSMA PET as a potential Imaging biomarker post tyrosine kinase inhibition of metastatic clear cell Renal cell Carcinoma	3	0
Peter MacCallum Cancer Centre	<b>Brett Hughes</b> (Cancer Care Services)	AURORA: AUstralian Registry Of thoRAcic cancers	4	32
Peter MacCallum Cancer Centre	<b>David Wyld</b> (Cancer Care Services)	NET SANGUIS: The potential role of circulating DNA in the management of neuroendocrine tumours.	3	0 In follow-up
Peter MacCallum Institute	<b>Anna Kuchel</b> (Cancer Care Services)	SUPER-NEXT: Complete Whole Genome Sequencing for Cancer of Unknown Primary	3	7 In follow-up
Queensland University of Technology	<b>Brett Hughes</b> (Cancer Care Services)	Liquid lung Biopsy: Laboratory Based Study of Circulating Tumour Cells in Human Blood	3	15 In follow-up
Southern Adelaide Local Health Network Incorporated	<b>Matthew Burge</b> (Cancer Care Services)	NEO-CREATE: Neoadjuvant Immune-Chemo-Radiotherapy in operable oEsophageal and gastro-oesophageal junction cancers with Carboplatin Paclitaxel Radiotherapy and Avelumab - a Trial assessing feasibility and preliminary Efficacy	3	10 In follow-up
Thoracic Oncology Group Australia	<b>Brett Hughes</b> (Cancer Care Services)	OCEANic: A Phase II, Open-label, Multi-centre Clinical Trial of Osimertinib With or Without Adjuvant Chemotherapy Guided by Tumour NGS Co-mutation Status and ctDNA Detection in Patients With Stage IIA-IIIA EGFR-Mutant Non Small Cell Lung Cancer Following Complete Surgical Resection	3	1
Thoracic Oncology Group Australia	<b>Brett Hughes</b> (Cancer Care Services)	SHERLOCK: Phase 2 trial of sotorasib in combination with carboplatin-pemetrexed and bevacizumab-biosimilar as first line treatment for advanced non-squamous non-small cell lung cancer with KRAS G12C mutation	3	4
Thoracic Oncology Group Australia	<b>Brett Hughes</b> (Cancer Care Services)	BR.31: A Phase III prospective double blind placebo controlled randomized study of adjuvant MEDI4736 in completely resected non-small cell lung cancer	3	8 In follow-up
Thoracic Oncology Group Australia	<b>Brett Hughes</b> (Cancer Care Services)	BR.34: A randomized trial of durvalumab and tremelimumab +/- platinum-based chemotherapy in patients with high-risk, metastatic (stage IV) squamous or non-squamous non-small cell lung cancer (NSCLC)	3	6 In follow-up
Thoracic Oncology Group Australia	<b>Brett Hughes</b> (Cancer Care Services)	DREAM3R: DuRvalumab (MEDI4736) with chEmotherapy as first line treAtment in advanced pleural Mesothelioma - A phase 3 Randomised trial	3	11 In follow-up



Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited
University of New South Wales	<b>David Wyld</b> (Cancer Care Services), Robert Henderson (Neurology)	IN FOCUS: Peripheral Neuropathy in Chemotherapy-treated Patients: Predictors, Assessment strategies and Functional Outcomes	3	59 In follow-up
Walter and Eliza Hall Institute	<b>Anna Kuchel</b> (Cancer Care Services)	iTestis: Bioinformatics for Testis Cancer	3	49
Walter and Eliza Hall Institute	<b>Chun Loo Gan</b> (Cancer Care Services)	KRAB: Kidney cancer Australian registry and Biobank	4	11
Walter and Eliza Hall Institute	<b>Matthew Burge</b> (Cancer Care Services)	PURPLE: Pancreatic cancer: Understanding Routine Practice and Lifting End results; A Prospective Pancreatic Cancer clinical registry	4	140
Walter and Eliza Hall Institute	<b>Michelle Nottage</b> (Cancer Care Services)	TABITHA: Study of the clinical outcomes and analysis of anti-HER2 therapy in treatment of metastatic HER2 positive breast cancer	4	31
Walter and Eliza Hall Institute	<b>Michelle Nottage</b> (Cancer Care Services)	ARORA: Advanced Hormone Receptor Positive Breast Cancer Registry in Australia	4	26 In follow-up
Walter and Eliza Hall Institute	<b>Matthew Burge</b> (Cancer Care Services)	Evaluation of temporal dynamics of RAS Mutation emergence in Cell Free DNA (cfDNA) in response to first-line cetuximab anti-EGFR therapy in Patients with Metastatic Colorectal Cancer	3	5 In follow-up
Walter and Eliza Hall Institute	<b>Matthew Burge</b> (Cancer Care Services)	DYNAMIC: Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Stage II Colon Cancer	3	22 In follow-up
Walter and Eliza Hall Institute	<b>Matthew Burge</b> (Cancer Care Services)	DYNAMIC III: Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Stage III Colon Cancer: A Multicentre Phase II/III Randomised Controlled Study (AGITG, WEHI)	3	42 In follow-up
Walter and Eliza Hall Institute	<b>Matthew Burge</b> (Cancer Care Services)	DYNAMIC-Pancreas: Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Early Stage Pancreatic Cancer: A Multicentre Randomised Study (WEHI, AGITG)	3	6 In follow-up
Walter and Eliza Hall Institute	<b>Zarnie Lwin</b> (Cancer Care Services)	EX-TEM: Phase III Trial of Extended Temozolomide in Newly Diagnosed Glioblastoma (WEHI)	3	5 In follow-up
Queensland University of Technology	<b>Jeffrey Goh</b> (Cancer Care Services), <b>Aneta Suder</b> (Cancer Care Services), Natasha Roberts (STARS)	IRONMAN: International registry for men with advanced prostate cancer	3	24
Patsy Yates (Palliative Care)	<b>David Wyld</b> (Cancer Care Services), Kimberly Alexander, Christine Miaskowski, Raymond Chan, Alexandra McCarthy, Steven McPhail, Helen Skerman	A sequential multiple assignment randomised trial (SMART) of nursing interventions to reduce pain associated with chemotherapy induced peripheral neuropathy	3	Not available
Teresa Brown (Nutrition and Dietetics)	Judy Bauer (University of Queensland), <b>Brett Hughes</b> (Cancer Care Services) Elizabeth Ahern	"Sarcopenia in HNSCC patients undergoing definitive concurrent CRT and associations with clinical outcomes"	4	Not available

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited
Connor O'Leary, (PAH)	Ken O'Byrne (PAH), Derek Richard (QUT), Elizabeth McCaffrey (PAH), Mark Adams (QUT), Arutha Kulasinghe (QUT), <b>Brett Hughes</b> (Cancer Care Services), Rahul Ladwah (PAH), Josh Burges (QUT)	Identification and clinical validation of potential cancer biomarkers	4	Not available

## Research Publications

### Authors

Investigator	ORCID ID	Investigator	ORCID ID
David Wyld	<a href="https://orcid.org/0000-0001-9523-4333">https://orcid.org/0000-0001-9523-4333</a>	Anna Kuchel	<a href="https://orcid.org/0000-0001-8580-2974">https://orcid.org/0000-0001-8580-2974</a>
Zarnie Lwin	<a href="https://orcid.org/0000-0003-1064-8444">https://orcid.org/0000-0003-1064-8444</a>	Mark Nalder	<a href="https://orcid.org/0000-0002-9310-1489">https://orcid.org/0000-0002-9310-1489</a>
Melissa Eastgate	<a href="https://orcid.org/0000-0002-7560-5026">https://orcid.org/0000-0002-7560-5026</a>	Michelle Nottage	<a href="https://orcid.org/0000-0002-1620-1961">https://orcid.org/0000-0002-1620-1961</a>
Chun Loo Gan	<a href="https://orcid.org/0000-0003-2576-9310">https://orcid.org/0000-0003-2576-9310</a>	Haidar Al-Saig	
Jeffrey Goh	<a href="https://orcid.org/0000-0003-3103-146X">https://orcid.org/0000-0003-3103-146X</a>	Matthew Burge	
Brett Hughes	<a href="https://orcid.org/0000-0002-1811-0537">https://orcid.org/0000-0002-1811-0537</a>	Po-Ling Inglis	
Aneta Suder		Darshit Thaker	

### Publications in 2024

#### Journal Articles (RBWH staff or consumers in bold)

Alexander M, Rogers J, Parakh S, Mitchell P, Clay TD, Kao S, **Hughes BGM**, Itchins M, Kong BY, Pavlakis N, Solomon BJ, John T. Lurbinectedin in small cell lung cancer: real-world experience of a multicentre national early access programme. Internal Medicine Journal. 2024. doi:10.1111/imj.16348. Epub 2024 Feb 18

Annageldiyev C, Gaudreau PO, Leitzel K, Ali SM, Ding K, Leighl NB, Badillo FEV, Bradbury PA, Goss GD, Shepherd LE, Costa L, Suva LJ, **Hughes BGM**, Stockler MR, Drabick JJ, Ma PC, Joshi M, Moku P, Polimera HV, Louis P, Ramachandula P, and Lipton A. Bone Metastasis is Associated with Worse Overall Survival in Patients with Stage IV Non-Small Cell Lung Cancer (NSCLC) Treated with Durvalumab and Tremelimumab with or without Chemotherapy: A Retrospective Analysis of the CCTG BR.34 Phase II Randomized Trial. JCO Oncology Advances. 2024 Nov;1:e2400017. doi:10.1200/OA.24.00017. Epub 2024 Nov 18

Blake C, Lai R, Brown T, Pelecanos A, Moroney L, Helios J, Smith D, **Hughes BGM**, Kenny L, Chua B, Bauer J. Nutrition outcomes and treatment toxicities in patients with head and neck cancer receiving helical intensity-modulated radiotherapy. Journal of Human Nutrition and Dietetics. 2024 Feb; 37(1):182-92. doi:10.1111/jhn.13243

Boyte F, Scanlon B, Matthews R, Button E, Jones L, Hayes T, Partridge G, Smith M, Kennedy G, **Eastgate M**, Gavin N. Bolusing IV Administration Sets With Monoclonal Antibodies Reduces Cost and Chair Time: A Randomized Controlled Trial. Clinical Journal of Oncology Nursing. 2024 Oct; 28(5):E9-15. doi:10.1188/24.CJON.E9-E15. Epub 2024 Oct 1

Brown TE, Byrnes A, Chan A, Dwyer K, Edwards A, Blake, CL, Banks MD, **Hughes BGM**, Lin CY, Kenny LK, Spurgin AL, Bauer JD. Revalidation of Proactive Gastrostomy Tube Placement Guidelines for Head and Neck Cancer Patients receiving Helical-Intensity Modulated Radiotherapy. Current Oncology. 2024 Nov;31(11):6938-55. doi:10.3390/currenco131110512. Epub 2024 Nov 6

**Burge ME**, Espinoza D, Sjoquist KM, Sui DH, Mercieca-Bebber R, Chantrill LA, Karapetis CS, Steer CB, Yip S, Cuff J, Winata S, Tie J, **Thaker DA**, Srivastav R, Abdi E, Strickland A, Segelov E, Francisconi A, Price T, Ladwa R, Joubert W, Tebbutt NC. AGITG MONARCC: A randomized phase 2 study of panitumumab monotherapy and panitumumab plus 5-Fluorouracil as first-line therapy for older patients with RAS and BRAF wild type metastatic colorectal cancer. A study by the Australasian Gastro-Intestinal Trials Group (AGITG). Clinical Colorectal Cancer. 2024. Epub 2024 Dec 12

## Journal Articles (RBWH staff or consumers in bold)

- Chin WL, Cook AM, Chee J, Principe N, Hoang TS, Kidman J, Hmon KPW, Yeow Y, Jones ME, Hou R, Denisenko E, McDonnell AM, Hon CC, Moody J, Anderson D, Yip S, Stockler MR, Kok PS, Brown C, John T, Kao SCH, Karikios DJ, O'Byrne KJ, **Hughes BGM**, Lake RA, Forrest ARR, Nowak AK, Lassmann T, Lesterhuis WJ. Coupling of response biomarkers between tumour and peripheral blood in mesothelioma chemoimmunotherapy. *Cell Reports Medicine*. 2024;101882. doi:10.1016/j.xcrm.2024.101882. Epub 2024 Dec 27
- Cho BC, Braña I, Cirauqui B, Aksoy S, Couture F, Hong RL, Miller W, Chaves-Conde M, Teixeira M, Leopold L, Munteanu M, Ge JY, Rahman A, **Hughes BGM**. Pembrolizumab plus Epacadostat in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304): a Phase 3, Randomized, Open-Label Study. *BMC Cancer*. 2024 July; 23(Suppl 1):1254. doi:10.1186/s12885-023-11316-0. Epub 2024 Jul 25
- Chow KV, Turner C, **Hughes B**, **Lwin Z**, Chan B. Real-world outcomes for patients with pleural mesothelioma: A multisite retrospective cohort study. *Asia-Pacific Journal of Clinical Oncology*. 2024 June;1-8. doi:10.1111/ajco.14098. Epub 2024 Jun 21.
- Conduit C, Davis ID, **Goh JC**, Kichenadasse G, Gurney H, Harris CA, Pook D, Krieger L, Parnis F, Underhill C, Adams D. A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinoma. *BJU International*. 2024 Feb; 133:57-67. doi:10.1111/bju.16190. Epub 2024 Feb 1
- Corvino D, Batstone M, **Hughes BGM**, Kempchen T, Ng SS, Salim NB, Schneppenheim F, Rommel D, Kumar A, Pearson S, Madore J, Koufariotis LT, Steinheuer LM, Pathirana D, Thurley K, Hasenauer J, Hölzel M, Borchering N, Engwerda C, Braun M, Bald T. Type I interferon drives a cellular state inert to TCR-stimulation and could impede effective T-cell differentiation in cancer. *European Journal of Immunology*. 2024. doi:doi.org/10.1002/eji.202451371. Epub 2024 Nov 12
- Emmett L, Subramaniam S, Crumbaker M, Nguyen A, Joshua AM, Weickhardt A, Lee ST, Ng S, Francis RJ, **Goh JC**, Pattison DA, Tan TH, Kirkwood ID, Gedye C, Rutherford NK, Sandhu S, Kumar AR, Pook D, Ramdave S, Nadebaum DP, Voskoboinik M, Redfern AD, Macdonald W, Krieger L, Schembri G, Chua W, Lin P, Horvath L, Bastick P, Butler P, Zhang AY, Yip S, Thomas H, Langford A, Hofman MS, McJannett M, Martin AJ, Stockler MR, Davis ID. [177Lu] Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial. *The Lancet Oncology*. 2024 May;25(5):563-71. doi:10.1016/S1470-2045(24)00135-9. Epub 2024 Apr 12
- Felip E, Metro G, Tan DSW, Wolf J, Mark M, Boyer M, **Hughes BGM**, Bearz A, Moro-Sibilot D, Le X, Puente Vazquez J, Massuti B, Tiedt R, Wang Y, Xu C, Mardjadi FI, Cobo M. Capmatinib Plus Nivolumab in Pretreated Patients With EGFR Wild-Type Advanced Non-Small Cell Lung Cancer. *Lung Cancer* 2024. June;192:107820. doi:10.1016/j.lungcan.2024.107820. Epub 2024 Jun 1
- Fong PC, Kwiatkowski M, Mosca A, Perez Valderrama B, Huang YH, Zedan AH, Kuc K, Wiechno P, Laguerre B, Gonzalez-Billalabeitia E, Osipov M, Dede DS, **Goh J**, Daugaard G, Zhu P, Imai K, Liu Y, Arranz Arijia JA. Coformulation of pembrolizumab and vibostolimab in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort G. *Journal of Clinical Oncology*. 2024 Jan; 42(Number 4\_suppl). doi:10.1200/JCO.2024.42.4\_suppl.149. Epub 2024 Jan 29
- Gately L, Mesía C, Sepúlveda JM, Del Barco S, Pineda E, Gironés R, Fuster J, Dumas M, Gill S, Navarro LM, Herrero A, Dowling A, de las Peñas R, Vaz MA, Alonso M, **Lwin Z**, Harrup R, Peralta S, Long A, Perez-Segura P, Ahern E, Garate O, Wong M, Campbell R, Cuff K, Jennens R, Gallego O, Underhill C, Martinez-Garcia M, Covela M, Cooper A, Brown S, Rosenthal M, Torres J, Collins IM, Gibbs P, Balana C. Exploring management and outcomes of elderly patients with glioblastoma using data from two randomised trials (GEINO1401/EX-TEM). *Journal of Neuro-Oncology*. 2024;1-8. doi.org/10.1007/s11060-024-04668-5. Epub 2024 Apr 17
- González-Martín A, Chung HC, Saada-Bouazid E, Yanez E, Senellart H, Cassier PA, Basu B, Corr BR, Girda E, Dutcus C, Okpara CE, Ghorri R, Jin F, Groisberg R, **Lwin Z**. Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study. *Gynecologic Oncology*. 2024 July;186():182-190. doi:doi.org/10.1016/j.ygyno.2024.04.011
- Hapgood G, Hill K, Okano S, Abro E, Looke D, Kennedy G, Pavilion G, Van Kuilenburg R, Geary A, Joubert W, **Eastgate M**, Jones M, Mollee P. Catheter-related thrombosis in adults with cancer: a secondary analysis of a prospective randomized controlled trial. *Journal of Thrombosis and Haemostasis*. 2024 Nov. doi:10.1016/j.jtha.2024.11.002. Epub 2024 Nov 15
- Hegewisch-Becker S, Mendez G, Chao J, Nemecek R, Feeney K, Van Cutsem E, Al-Batran SE, Mansoor W, Maisey N, Pazo Cid R, **Burge M**, Perez-Callejo D, Hipkin W, Mukherjee S, Lei M, Tang H, Suryawanshi S, Kelly R, Tebbutt N. First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study. *Journal of Clinical Oncology*. 2024 May. doi.org/10.1200/JCO.23.01636. Epub 2024 May 9
- Hovelroud R, Goh Xiu Ming S, McLeod DS, Donovan PJ, **Ng G**, Mungomery M. A Case of Enfortumab Vedotin-Associated Diabetic Ketoacidosis With Severe Insulin Resistance in a Nondiabetic Woman. *JCEM Case Reports*. 2024 Dec; 2(12):luae212. doi:10.1210/jcemcr/luae212. Epub 2024 Nov 25
- Jalali A, Smith S, Kim G, Wong H, Lee M, Yeung J, Loft M, Wong R, Shapiro JD, Kosmider S, Tie J, Ananda S, Ma B, **Burge M**, Jennens R, Lee B, Johns J, Lim L, Dean A, Nott L, Gibbs P. Early onset metastatic colorectal cancer in Australia. *Cancer Treatment and Research Communications*. 2024 Jun; 40():100827. doi:10.1016/j.ctarc.2024.100827. Epub 2024 Jun 12
- Ladwa R, Chandra J, Woo WP, Finlayson N, Liu HY, McGrath M, See AM, **Hughes BGM**, Cooper C, Jackson J, Dzienis M, Xu Y, Panizza B, Frazer, IH, Porceddu, SV. A Phase 1b, single centre, open label study to assess the safety, tolerability and immunogenicity of a therapeutic human papillomavirus (HPV) DNA vaccine (AMV002) in combination with durvalumab for HPV-associated PD-L1 positive recurrent/ metastatic head and neck squamous cell carcinoma. *Frontiers in Oncology*. 2024 Jul; 14():1419258. doi:10.3389/fonc.2024.1419258. Epub 2024 Jul 5

## Journal Articles (RBWH staff or consumers in bold)

- Li T, Timmins HC, Mahfouz FM, Trinh T, Mizrahi D, Horvath LG, Harrison M, Grimison P, Friedlander M, Marx G, Boyle F, **Wyld D**, Henderson R, King T, Baron-Hay S, Kiernan MC, Rutherford C, Goldstein D, Park SB. Validity of Patient-Reported Outcome Measures in Evaluating Nerve Damage Following Chemotherapy. *JAMA Network Open*. 2024 Aug 1;7(8):e2424139. doi:10.1001/jamanetworkopen.2024.24139. Epub 2024 Aug 9
- Machiels JP, Tao Y, Licitra L, Burtness B, Tahara M, Rischin D, Alves G, Lima IP, **Hughes BGM**, Pointreau Y, Aksoy S, Laban S, Greil R, Burian M, Hetnal M, Delord JP, Mesía R, Taberna M, Waldorn J, Simon C, Grégoire V, Harrington K, Swaby RF, Zhang Y, Gumuscu B, Bidadi B, Siu LL. Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial. *The Lancet Oncology*. 2024. doi:10.1016/S1470-2045(24)00100-1. Epub 2024 Mar 29
- Mak B, Tran B, Pashankar FD, Mazhar D, Huddart RA, Wheeler M, Walpole ET, Feldman DR, Dunwoodie E, Lawrence NJ, Birtle AJ, **Wyld D**, Stevanovic AG, Balagtas JMS, Stockler MR, Davis ID. P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-45 years with intermediate and poor-risk metastatic germ cell tumours (GCTs). *Journal of Clinical Oncology*. 2024 Jan; 42(Number 4\_suppl). doi:10.1200/JCO.2024.42.4\_suppl.TPS524. Epub 2024 Jan 29
- Matthews R**, Russell E, Wessling C, Sandler CX, **Eastgate M**, Hajkowicz K, Pavey T, Clark BK, **Scanlon B**, **Gavin N**. Exploring the administration of intravenous antibiotics and fluids via portable intravenous pump versus intravenous pump and pole to improve mobility in patients diagnosed with cancer (The ACTIVE Trial): A randomized controlled trial protocol. *Vascular Access*. 2024 18(2):44-58. doi:10.5737/va.v18.i2.44. Epub 2024 Sep 25
- McLean LS, Lim AM, Bressel M, Lee J, Ladwa R, Guminski AD, **Hughes B**, Bowyer S, Briscoe K, Harris S, Kukard C. Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort study. *Medical Journal of Australia*. 2024 Feb;220(2):80-90. doi:10.5694/mja2.52199. Epub 2024 Jan 11
- Ngo P, Ahmadi N, Ferguson P, Conduit C, O'Haire S, **Kuchel A**, Pranavan G, Weickhardt A, Tran B, Grimison P. Characteristics and outcomes among patients with delayed orchidectomy for advanced germ cell tumours. *BJU international*. 2024 Oct. doi:10.1111/bju.16546. Epub 2024 Oct 10
- Pook DW, Harris CA, Link E, **Goh JC**, Parnis F, Gurney H, Kichenadasse G, Underhill C, Torres J, Roncolato F, Inderjeeth AJ, Conduit C, McJannett MM, Davis ID, Gedye C. UNICAB: Cabozantinib in locally advanced or metastatic non-clear cell renal cell carcinoma post immunotherapy or in those unsuitable for immunotherapy (ANZUP 1802). *Journal of Clinical Oncology*. 2024 Jan; 42(Number 4\_suppl). doi:10.1200/JCO.2024.42.4\_suppl.428. Epub 2024 Jan 29.
- Porceddu SV, Negrello T, Rawson N, Dunn N, Batstone M, Collins M, Dowthwaite S, **Hughes BGM**, Kenny L, Ladwa R, Panizza B, Cossio D. Human Papillomavirus (HPV) associated oropharyngeal cancer now the most common mucosal head and neck cancer in Queensland. *Journal of Medical Imaging and Radiation Oncology*. 2024. doi:10.1111/1754-9485.13643. Epub 2024 Apr 23
- Rischin D, **Hughes BGM**, Basset-Séguin N, Schadendorf D, Bowyer S, Messai ST, Meier F, Eigentler TK, Echarren VC, Stein B, Beylot-Barry M, Dalac S, Dreno B, Migden MR, Hauschild A, Schmults CD, Lim AM, You SY, Paccaly AJ, Papachristos A, Nguyen JH, Okoye E, Sebach F, Booth J, Lowy I, Fury MG, Guminski A. High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma. *Journal for ImmunoTherapy of Cancer*. 2024;12(3). doi:10.1136/jitc-2023-008325. Epub 2024 Mar 11
- Roberts NA, Esler R, Pearce A, **Wyld D**, Smith M, Woollett K, Mazariego C, Roberts MJ. Exploring Unmet Needs in Prostate Cancer Care: A Cross-sectional Descriptive Study. *European Urology Open Science*. 2024 April; 62:36-42. doi.org/10.1016/j.euros.2024.01.018
- Roberts NA, Pelecanos A, Alexander K, **Wyld D**, Janda M. Implementation of Patient-Reported Outcomes in a Medical Oncology Setting (the iPROMOS Study): Type II Hybrid Implementation Study. *Journal of Medical Internet Research*. 2024 Aug; 26.e55841. doi:10.2196/55841. Epub 2024 Aug 27
- Roth S, Wilson KC, Ramsay RG, Mitchell C, Sampurno S, Pham TD, Kong J, Wong SQ, Heriot AG, Deva S, **Burge M**, Sverdrup C, Moller A, Kuryk L, Eriksen JA, Jaderberg M, Zalcborg JR, Michael M. A non-randomised open-label exploratory 'window of opportunity' study of TG02 treatment in patients with locally advanced primary and recurrent RAS mutant colorectal cancer. *Heliyon*. 2024 Dec; 11(1):e41364. doi:10.1016/j.heliyon.2024.e41364. Epub 2024 Dec 19
- Sadeghirad H, Monkman J, Liu N, Tan CW, Yunis J, Donovan ML, Moradi A, Jhaveri N, Perry C, Adams M, O'Byrne K, Warkiani ME, Ladwa R, **Hughes BGM**, Kulasinghe A. Spatial dynamics of tertiary lymphoid aggregates in head and neck cancer: insights into immunotherapy response. *Journal of Translational Medicine*. 2024 Jul;22(1):677. doi:10.1186/s12967-024-05409-y. Epub 2024 Jul 24
- Solomon BJ, Dagogo-Jack I, Lee S-H, Boyer M, Ramalingam S, Carcereny E, Felip E, Han J-Y, Hida T, **Hughes BGM**, Im S-W, Nisho M, Seto T, Okamoto T, Zhang X, Martini J-F, Wang E, DeBeukelaer S, Bauer T. Avelumab in combination with either crizotinib or lorlatinib in patients with previously treated advanced NSCLC: phase 1b/2 results from the JAVELIN Lung 101 trial. *JTO Clinical and Research Reports*. 2024 July; 5(7):100685. doi:10.1016/j.jtocrr.2024.100685. Epub 2024 Jul 1
- Takashima A, García-Alfonso P, Manneh R, Besen AA, Hong YS, Cuyle PJ, Yanez P, **Burge M**, Yoshino T, Kim TW, Cui K. Olaparib with or without bevacizumab versus bevacizumab plus a fluoropyrimidine as maintenance therapy in advanced colorectal cancer: The randomized phase 3 LYNK-003 study. *European Journal of Cancer*. 2024:114036. doi:10.1016/j.ejca.2024.114036. Epub 2024 Mar 21



**Journal Articles (RBWH staff or consumers in bold)**

Tariq A, Pearce A, Rhee H, Kyle S, Raveenthiran S, Pelecanos A, **Gan CL, Goh JC**, Wong D, McBean R, Marsh P, Goodman S, Dunglison N, Esler R, Navaratnam A, Yaxley JW, Thomas P, Pattison DA, Roberts M. The Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Primary Staging of Selected Renal Tumours: Initial Experience in a Multicentre Cohort. *European Urology Focus*. 2024. doi:10.1016/j.euf.2023.12.004. Epub 2024 Jan 8

Webb PM, Brown A, Brown B, Collins LG, Crawford-Williams F, Doupain K, **Eastgate M**, Fennelly V, Girgis A, Harte G, Ladwa R, Martin K, Mason R, McGuire P, Miller E, O'Brien S, Packer R, Pinkham MB, Sabesan S, Sanmugarajah J, Slapp G, Tapsall D, White J, Wishart LR, **Wyld D**, Chan RJ. Patient Reported Outcome Measures in cancer care: a hybrid effectiveness-Implementation trial to optimise Symptom control and health service Experience (PROMISE) - protocol for a randomised controlled trial of electronic self-reporting of symptoms versus usual care during and following treatment in patients with cancer. *BMJ Open*. 2024 (14):e090836. doi:10.1136/bmjopen-2024-090836. Epub 2024 Nov 19

White C, Wardill H, Paul C, Price T, Karapetis C, **Nalder M, Burge ME**, Thomas A, Oldmeadow C, Barker D, Edney LC, Collier J, Bowen J, Ostroff C, Cheek B, Carlson M, Rankmore T, Nagrial A, Clarke S, Chantrill L, Ackland S, Scott RJ. DPYD genotype-guided dose personalisation for fluoropyrimidine-based chemotherapy prescribing in solid organ cancer patients in Australia: GeneScreen 5-FU study protocol. *BMC Cancer*. 2024 Nov; 24(1):1369. doi:10.1186/s12885-024-13122-8. Epub 2024 Nov 8

Xia Q, Senanayake SJ, Kularatna S, Brain D, McPhail SM, Parsonage W, **Eastgate M**, Barnes A, Brown N, Carter HE. Cost-Effectiveness Analysis of Microwave Ablation versus Robot-Assisted Partial Nephrectomy for patients with Small Renal Masses in Australia. *Urologic Oncology: Seminars and Original Investigations*. 2024 Oct. doi:10.1016/j.urolonc.2024.09.016. Epub 2024 Oct 4

Yap N, Wong V, Morton C, de Boer R, Baron-Hay S, Blum R, Forster B, Chua S, Clarke K, Cuff K, Green M, Lim E, Mok K, Nott L, **Nottage M**, Tafreshi A, Tsoi D, Uccellini A, Gibbs P, Lok SW. Medicine Access Programs – what do patients think: A patient reported outcome study on ribociclib in metastatic breast cancer in Australia. *Internal Medicine Journal*. 2024 Oct. doi:10.1111/imj.16536. Epub 2024 Oct 28

Zhang X, Weeramange CE, **Hughes BGM**, Vasani S, Liu ZY, Warkiani M, Hartel G, Ladwa R, Thiery JP, Kenny L, Breik O, Punyadeera C. Circulating tumour cells predict recurrences and survival in head and neck squamous cell carcinoma patients. *Cellular and Molecular Life Sciences*. 2024 May;81():233. doi:10.1007/s00018-024-05269-1. Epub 2024 May 23.

**Keynote or Plenary Lectures given in 2024**

Date	Title
20 AUG 2024	<b>Lwin, Z.</b> New Landscape for low grade gliomas including IDH1 inhibitors. Neurosurgical Society of Australasia Annual Scientific Meeting
13 NOV 2024	<b>Eastgate M.</b> Removing barriers of access to care with technology. Clinical Oncology Society of Australia ASM 2024



Left to right back row: Denise Flynn, Marketa Pauley, Laura Chazikantis, Michelle Cybulski, Sarah Gunning, Sharon Harney, Allison Hyde, Poppy Sharman, Liam Ceh

RBWH Research Report 2024

Cancer Care Services

Page 37 of 48



Front row: Fiona Davis (white blouse), Beth Spear, Amy Ives, Megan Ward, Jade Allan, Jasmine Brady, Dianna Lewis, Verna Yvanoff



Left to right: Jennifer Edmunds, Kirsten Popplewell, Melissa Eastgate, Michelle Cybulski, Amy Ives, Jacqui Keller, Robyn Western, Renee Campbell, Michael Smith

# Cancer Care Nursing Research



**Mr Michael Smith**  
**Director Cancer Nursing, RBWH**

2024 has been an exciting year for the Cancer Care Nursing Research Team. We welcomed Professor Kim Alexander from Queensland University of Technology to our team, who has taken on a joint appointment as Professor of Cancer Nursing between QUT and RBWH. Kim brings a wealth of knowledge and experience as an oncology nurse, academic and researcher. Along with our team of Nurse Researchers, Kim has played an integral role in the development of our ambitious Nursing Research Action Plan (2024-2027). This plan outlines our research priorities as well as opportunities for growth and capacity building across the service line.


Nurse Researcher Dr Brighid Scanlon officially graduated from her PhD in 2024, disseminating her findings at several local and national conferences. Notably, presenting in the *Best of the Best* (Equity stream) at the Clinical Oncology Society of Australia Annual Scientific Meeting (COSA ASM). We congratulate Brighid on these wonderful achievements.

The research team has continued to support the work of our research interns and higher degree research students. Intern Emma Munro presented at the MASCC Conference in Lille, France, the 2024 Blood Conference and at the Metro North Nursing and Midwifery Showcase. Intern Yu-Meng Shu also presented at the Nursing and Midwifery Showcase, winning the *Best Quality Improvement Project Award*. Intern Hannah Warriner has commenced her Master of Philosophy at QUT, Faculty of Health, securing a competitive faculty scholarship for 2025.

The Nursing Research Team were successful in securing two Foundation Project Grants, led by Professor Kim Alexander and Dr Brighid Scanlon. These projects will focus on developing a Wellness Model of Care for patients undergoing immunotherapy and pilot testing an equity framework to reduce failure to attend appointments. These exciting projects are scheduled to commence in the first quarter of 2025.

We congratulate the Cancer Care Nursing Research team on their outstanding achievements in 2024 and look forward to an exciting 2025.

## Successful Research Higher Degree candidates in 2024

Name	Title	Month Competed	Affiliated University	Summary
Brighid Scanlon (PhD)	Equity Across the Cancer Care Continuum for Culturally and Linguistically Diverse Migrants Living in Australia	July 2024	Queensland University of Technology	This thesis explored equity for Culturally and Linguistically Diverse migrant populations across the continuum of cancer care in Queensland, Australia. This three-phase mixed-methods study summarised the current level of evidence for equity, identified previously unknown inequities across the cancer continuum, and explored the structural and institutional factors that influence the provision of equitable care. This critical examination of equity challenges assumptions, language and practices and provides actionable recommendations for Australian health services to enable the operationalisation of health equity.
				

## Research Awards and Achievements

Recipient (RBWH staff in bold)	Award	Event
Emma Munro	Australian College of Nursing Emerging Research Leaders Program	\$10,000 to support research project
Courtney Black	QUT MPhil Stipend	\$30,000 per annum 2024-2025
Brighid Scanlon	Finalist	Metro North Research Excellence Awards
Yu-Meng Shu	Best Quality Improvement Project	Metro North Nursing and Midwifery Showcase
Robyn Western and Renee Campbell	HSANZ Nurse Group Best Poster 2024	Blood 2024 Conference

## Research Grants

Investigator Names (RBWH staff in bold)	RBWH Departments / Research Groups	Research Project Title	Granting Body	Total Awarded (whole all years)	Length of Awards in years and years active
<b>Robyn Matthews,</b> Toby Pavey, <b>Nicole Gavin,</b> <b>Melissa Eastgate,</b> Bronwyn Clark, Greg Merlo, <b>Brighid Scanlon</b>	CCS Nursing Research	A randomised controlled trial exploring the administration of intravenous antibiotics and fluids via intravenous pole and pump versus portable CADD pump to improve mobility in patients diagnosed with cancer (The Active Trial)	Metro North Collaborative Research Grant (QUT and MN)	\$49,964.25	3 years, 2022 - 2024
<b>Sarah Andersen,</b> <b>Andrea Hendon,</b> <b>Midori Nakagaki,</b> <b>Nicole Gavin,</b> <b>Glen Kennedy &amp; Heidi Staudacher</b>	Allied Health, CCS Nursing Research, Haematology, Pharmacy	Prebiotic fibre supplementation in haematology	Gateway for Cancer Research	\$112,000 USD	2 years, 2023-2024
<b>Sarah Andersen,</b> <b>Andrea Hendon,</b> <b>Midori Nakagaki,</b> <b>Nicole Gavin,</b> <b>Glen Kennedy &amp; Heidi Staudacher</b>	Allied Health, CCS Nursing Research, Haematology, Pharmacy	Prebiotic fibre supplementation to improve patient outcomes during allogeneic stem cell transplantation, a pilot randomised control trial	SERTA Project Grant	\$71,165	2 years, 2023-2024
<b>Sarah Andersen,</b> <b>Andrea Hendon,</b> <b>Midori Nakagaki,</b> <b>Nicole Gavin,</b> <b>Glen Kennedy &amp; Heidi Staudacher</b>	Allied Health, CCS Nursing Research, Haematology, Pharmacy	Prebiotic fibre supplementation during allogeneic stem cell transplantation, a pilot randomised control trial	American Society of Parenteral and Enteral Nutrition Rhoads Research Foundation	\$20,000 USD	2 years, 2023-2024
<b>Veronica Percival,</b> <b>Nicole Gavin,</b> Kirsty McLeod, <b>Therese Hayes</b>	CCS Nursing Research	Implementing a lumbar puncture nursing assessment tool to support clinical practice and improve patient care	MN Research SWIFT Grant	\$14,902	2 years, 2023-2024

## RBWH Department / Research Group Led Research Activity

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited
<b>Mary-Ellen Yarker</b>	Carol Windsor (QUT) Jennifer Fox (QUT) Pauline Gillan (QUT)	The role of oncology nurse in shared decision making for patients undergoing radiation and/or chemotherapy treatment	Ongoing	

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited
<b>Judy Avery</b>	Sonya Osborne (USQ), Aletha Ward (USQ), Catriona Brooker (USQ)	Nurse-led debriefing with hospital nurses in the workplace	Ongoing	
<b>Hannah Warriner, Kim Alexander, Nicole Gavin</b>		The psychological experience of oncology patients secondary to a hypersensitivity reaction	Ongoing	
<b>Emma Munro, Brigid Scanlon, Nicole Gavin, Michaela Teevan, Eleanor Green, Cameron Curley, Michael Smith</b>		Development of a clinical pathway for mucositis assessment and management in haematopoietic stem cell transplantation: Improving practice and standardising nursing care	Ongoing	

## Collaborative Research Activity Involving RBWH Department / Research Group

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited
Emily N Larsen, Claire M Rickard, Nicole Marsh, Mary Fenn, Rebecca S Paterson, Amanda J Ullman, Raymond Chan, Vineet Chopra, Doreen Tapsall, Amanda Corley, <b>Nicole Gavin, Brigid Scanlon, Joshua Byrnes</b>		Patient reported outcome and experience measures among patients with Central Venous Access Devices	Ongoing	
<b>Natasha Roberts, Michael Smith, David Wyld, Teresa Brown, Leonie Naumann, Erin Molloy, Suzette Fox, Greg Lewis, Mandy Fairclough, Maree Gier, Kieren Barker, Therese Hayes, Jenni Leutenegger, Nicole Gavin and Elise Button.</b>	Gary Power (RBWH Consumer) and Helene Jacmon (Consumer representative)	A co-designed implementation science strategy with clinicians, consumers and researchers to structure improved nurse-led symptom management in medical oncology care	Ongoing	

## Research Publications

### Authors

Investigator	ORCID ID	Investigator	ORCID ID
Nicole Gavin	<a href="https://orcid.org/0000-0002-0828-9852">https://orcid.org/0000-0002-0828-9852</a>	Francesca Boyte	NA
Brigid Scanlon	<a href="https://orcid.org/0000-0002-9190-8721">https://orcid.org/0000-0002-9190-8721</a>	Kimberly Alexander	<a href="https://orcid.org/0000-0003-3906-2412">https://orcid.org/0000-0003-3906-2412</a>
Robyn Matthews	<a href="https://orcid.org/0000-0003-3828-5278">https://orcid.org/0000-0003-3828-5278</a>	Patsy Yates	<a href="https://orcid.org/0000-0001-8946-8504">https://orcid.org/0000-0001-8946-8504</a>
Veronica Percival	<a href="https://orcid.org/0000-0001-7821-8710">https://orcid.org/0000-0001-7821-8710</a>	Elise Button	<a href="https://orcid.org/0000-0001-8240-8699">https://orcid.org/0000-0001-8240-8699</a>

## Publications in 2024

### Journal Articles (RBWH staff or consumers in bold)

**Midori Nakagaki, Glen A Kennedy, Nicole C Gavin, Jason Butler, Alexandra Clavarino & Karen Whitfield** (2024) A randomised trial of topical polaprezinc to prevent oral mucositis in patients undergoing haematopoietic stem cell transplantation (ToPaZ study). Supportive Care in Cancer 32. DOI: 10.1007/s00520-023-08235-y

**Rob Boots, Cameron Curley, Ashleigh Scott, Nicole Gavin, Edward Morris, Carley Foster, Matthew Jackson, Sally Collet, Damien Thompson, Nadine Wardell, James Vedelago & Stephen Adam** (2024) Virtual reality experience in haemato-oncology patients—technical evaluation (ViREB-TE). BMC Digit Health 2, 6. DOI: 10.1186/s44247-023-00060-x



### Journal Articles (RBWH staff or consumers in bold)

Natasha Roberts, **Elise Button**, **Jed Duff**, Catharine Paterson, **Michael Smith & Nicole C Gavin** (2024) Clinical research nursing pathways: The development and evaluation of a nursing research internship program using the RE-AIM framework. *International Journal of Nursing Studies Advances*. DOI: 10.1016/j.ijnsa.2024.100176

**Nicole C. Gavin**, Sarah Northfield, Gabor Mihala, **Margaret Somerville**, Tricia Kleidon, **Nicole Marsh**, Emily Larsen, Jill Campbell, Claire M. Rickard & Amanda J. Ullman (2024) Central Venous Access Device–Associated Skin Complications in Adults with Cancer: A Prospective Observational Study. *Seminars in Oncology Nursing*. DOI:10.1016/j.soncn.2024.151618

**Fran Boyte, Robyn Matthews, Elise Button, Lee Jones, Therese Hayes, Grant Partridge, Michael Smith, Glen Kennedy, Melissa Eastgate & Nicole C Gavin** (2024) Does bolusing intravenous administration sets with monoclonal antibodies reduce chair time in the oncology outpatient setting? A protocol for a randomised controlled trial. *Canadian Journal of Vascular Access* (accepted for publication)

Amanda Corley, Ruth H Royle, Nicole Marsh, Emily N. Larsen, E. Geoffrey Playford, Matthew R. McGrail, Naomi Runnegar, Robert S. Ware, **Nicole C. Gavin**, Evan Alexandrou, Marghie Murgo, John R. Gowardman, Adrian Regli, Claire M. Rickard (2024) Incidence and risk factors for central venous access device failure in hospitalized adults: A multivariable analysis of 1892 catheters. *Journal of Hospital Medicine*. DOI: 10.1002/jhm.13414

**Scanlon, B. Boyte, F. Matthews, R. Button, E. Jones, L. Hayes, T. Partridge, G. Smith, M. Kennedy, G. Eastgate, M. Gavin, N.** (2024) Bolusing intravenous administration sets with monoclonal antibodies reduces cost and chair time in the oncology outpatient setting: Results of a randomised control trial. *Clinical Journal of Oncology Nursing*. DOI: 10.1188/24.CJON.E9-E15

**Matthews, R.**, Russell, E., Wessling, C., Sandler, C., **Eastgate, M., Hajkowicz, K.**, Pavey, T., Clark, B.K., **Scanlon, B., & Gavin, N.C** (2024). Exploring the administration of intravenous antibiotics and fluids via portable intravenous pump versus intravenous pump and pole to improve mobility in patients diagnosed with cancer (The ACTIVE Trial): A randomized controlled trial protocol. *Vascular Access – Journal of the Canadian Vascular Access Association* (18) 2

Singh, K., **Mudge, A., Matthews, R.**, Yates P., Phillips, J., Virdun, C. (2024) Quality of care from the perspectives of inpatients with palliative care needs: A cross-sectional study of patient reported experience data. *BMC Palliative Care* (accepted for publication)

**Button, E.** Carter, H. **Gavin, N.** LeBlanc, TW. McCaffrey, N. (2024) A systematic review of health state utility values for older people with acute myeloid leukaemia. *Quality of Life Research*. DOI: [10.1007/s11136-024-03734-9](https://doi.org/10.1007/s11136-024-03734-9)

Larsen, E. Rickard, C. Marsh, N. Fenn, M. Paterson, R. Ullman, A. Chan, R. Chopra, V. Tapsall, D. Corley, A. **Gavin, N.** **Scanlon, B.** Byrnes, J. (2024) Patient reported outcome and experience measures among patients with Central Venous Access Devices: A systematic review. *Supportive Care in Cancer*. (accepted for publication).

### Book Chapters (RBWH staff or consumers in bold)

Kerrie Curtis, **Nicole C Gavin** & Catriona Duggan (2024) Part II Chapter 4 Right Patient Selection. Moureau N (Editor) *Vessel Health and Preservation: The Right Approach for Vascular Access*. Second Edition.

## Keynote or Plenary Lectures given in 2024

Date	Title
19th June 2024	<b>Nicole Gavin</b> : Cancer Nurses Society of Australia Pre-Congress Symposium – Vascular Access Device Dressing Management: Evidence, Practice, Products, Documentation and Data
19th June 2024	<b>Kim Alexander</b> : <i>Nursing at the Forefront of Genomics, Innovative quality care in a digital era</i> , Cancer Nurses Society of Australia, Brisbane
12th July 2024	<b>Kim Alexander</b> : The Queensland Collaborative for Cancer Survivorship Mid-Year Seminar, Brisbane
6th August 2024	<b>Kim Alexander</b> : <i>The countdown is on: how science is transforming the future of cancer care</i> , <i>Rare Cancer Moonshot</i> , CanForum, Canberra
13 <sup>th</sup> November 2024	<b>Brigid Scanlon</b> : <i>When good intentions are not enough: Development of the Equity Process Framework to promote equity in cancer</i> . Clinical Oncology Society of Australia, Gold Coast
15 <sup>th</sup> November 2024	<b>Yu-Meng Shu</b> : <i>Developing a standardised pathway for the management of Gynaecological and Prostate Brachytherapy</i> . Metro North Nursing and Midwifery Showcase, Herston
15 <sup>th</sup> November 2024	<b>Emma Munro</b> : <i>Oral mucositis management in Haematopoietic Stem Cell Transplantation in Australia and New Zealand</i> . Metro North Nursing and Midwifery Showcase and Blood Conference 2024



# Allied Health Professions



**Dr Clare Burns**  
**Advanced Speech Pathologist (Cancer Care)**  
**Speech Pathology Department**

Across 2024, Allied Health Professions has led multidisciplinary research with the teams of radiation oncology, medical oncology, haematology/BMT and we have continued collaboration with aligned RBWH services and research centres, such as QIMR. We have also continued to conduct research with academic centres throughout Australia and overseas.

Our research has developed and examined outcomes relating to innovative treatments, new care pathways and healthcare models and explored the lived experience of our consumers to identify their supportive care needs to optimise their outcomes and healthcare experience.

Allied Health Professions received several awards and achievements across 2024.

Key highlights include:

- ❖ Christine Johnson and the Dietetics and Food Services research team was awarded the New Presenter award at the 2024 Dietitians Australia National Conference.
- ❖ Belinda Lehn (Speech Pathology) in collaboration with clinicians from ENT, Dietetics and Food Services, Physiotherapy, and a consumer representative received the Consumer Focus Project Award at the RBWH QuARRIES for the project, “Sharing Consumer Experiences Across the Laryngectomy Journey”.
- ❖ A total of \$314,000 in new grants (commencing in 2024) were awarded to AHP researchers. Of note, Dr Sarah Anderson (Dietetics and Food Services) and her research team were awarded \$266,165 for studies focusing on prebiotic fibre supplementation during allogeneic stem cell transplantation.
- ❖ 11 research studies were led by Allied Health clinician researchers and 8 in collaboration with other teams.
- ❖ 7 peer reviewed publications and 10 national and international keynote presentations were delivered.

Three research higher degree students with a focus on cancer care were supervised by Allied Health staff. These research programs are conducted in collaboration with RBWH clinician researchers to support research translation and optimise patient outcomes and service benefits.

## Research Awards and Achievements

Recipient (RBWH staff in bold)	Award	Event
<b>Belinda Lehn, Clare Burns, Sarju Vasani, Rebecca Fichera, Charlotte Hockey, Brien Hands</b>	Consumer Focus Project Award	RBWH QuARRIES
Christine Johnson, <b>Sarah Andersen, Teresa Brown, Rachel Willims, Helen MacLaughlin</b>	Winner, New Presenter	Dietitians Australia National Conference 2024

## Research Grants

Investigator Names (RBWH staff in bold)	RBWH Departments / Research Groups	Research Project Title	Granting Body	Total Awarded (whole all years)	Length of Awards in years and years active
<b>Sarah Andersen</b>	Dietetics and Food Services	Using prebiotic fibre supplementation to improve patient outcomes during treatment for haematological malignancies	Metro North Health Fellowship stimulus grant	\$240,531	5 years, 2023-2027
<b>Sarah Andersen</b> , Heidi Staudacher (Deakin Uni), Nicole Gavin (Cancer Care), Andrea Henden (QIMR, UQ)	Dietetics and Food Services, Cancer Care Services	Prebiotic fibre supplementation during allogeneic stem cell transplantation, a pilot randomised control trial	ASPEN Rhoads Research Foundation grant	\$30,200	1 year, 2024
<b>Sarah Andersen</b> , Heidi Staudacher (Deakin Uni), Nicole Gavin (Cancer Care), Andrea Henden (QIMR, UQ)	Dietetics and Food Services, Cancer Care Services	Prebiotic fibre supplementation during allogeneic stem cell transplantation, a pilot randomised control trial	SERTA Project grant	\$71,165	1 year, 2024
<b>Sarah Andersen</b> , Heidi Staudacher (Deakin Uni), Nicole Gavin (Cancer Care), Andrea Henden (QIMR, UQ)	Dietetics and Food Services, Cancer Care Services	Prebiotic fibre supplementation during haematological cancer treatment	GFCR Grants Program	\$165,000	2 years, 2024-2026
<b>Teresa Brown</b>	Dietetics and Food Services	Optimising nutrition outcomes and care pathways for patients undergoing surgical resection for head and neck cancer	Metro North Clinician Research Fellowship	\$175,000	3 years, 2022-2025
<b>Teresa Brown</b>	Dietetics and Food Services	Immunotherapy and nutrition outcomes in head and neck cancer	Metro North Health Fellowship Stimulus Grant	\$10,000	1 year, 2024
<b>Frances Thomsen</b> , <b>Michelle Donovan</b> , <b>Karina Lewis</b> , <b>Sue Laracy</b> , <b>Omar Breik</b>	Occupational Therapy, Maxillofacial Surgery.	The impact of immobilisation orthoses on radial forearm flap donor sites in patients with head and neck cancer – a retrospective chart audit	RBWH Foundation Extraordinary Grants	\$14,984	2 years, 2022-2024

## RBWH Department / Research Group Lead Research Activity

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited
<b>Sarah Andersen</b>	<b>Teresa Brown</b> , Glen Kennedy (Cancer Care), Frederik Steyn (Neurology & UQ), <b>Rachel Willims</b>	Energy expenditure in patients undergoing allogeneic stem cell transplantation	4	13
<b>Sarah Andersen</b>	Andrea Henden (QIMR), Glen Kennedy (Cancer Care), <b>Merrilyn Banks</b>	Prebiotics, the gastrointestinal microbiome, and clinical outcomes post allogeneic stem cell transplantation	4	n/a

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited
<b>Sarah Andersen</b>	Andrea Henden, Heidi Staudacher (Deakin), Jacinta Smith (Consumer) Midori Nakagaki, Nicole Gavin (Cancer Care)	Prebiotic fibre supplementation during allogeneic stem cell transplantation, a pilot randomised control trial	4	12
<b>Teresa Brown</b>	Daniel Hwang (UQ), <b>Elise Treleaven</b> , Brett Hughes (Cancer Care), Liz Kenny (Cancer Care), Charles Lin (Cancer Care), Penny Webb (QIMR), Anita Pelecanos (QIMR), Judy Bauer (Monash)	A feasibility study to investigate taste changes post treatment in patients with head and neck cancer and their association with genes and dietary behaviour		
<b>Teresa Brown</b>	Ryan Sommerville (ENT), Tom Slaughter (ENT), <b>Clare Burns</b> , Brett Hughes (Cancer Care), Judy Bauer (Monash)	Nutrition and swallowing outcomes following transoral robotic surgery for head and neck cancer	4	9
<b>Teresa Brown</b>	Ryan Sommerville (ENT), Abigail Walker (ENT), Stephanie Yau (ENT), <b>Joanne Hiatt, Rebecca Fichera, Clare Burns</b> , Brett Hughes (Cancer Care), Judy Bauer (Monash)	Nutrition and swallowing outcomes following skull base surgery	4	18
<b>Teresa Brown</b>	<b>Belinda Camilleri</b> , Brett Hughes (Cancer Care), Judy Bauer (Monash)	Nutrition outcomes following immunotherapy for head and neck cancer	4	89
<b>Clare Burns</b>	Annie Hill (UQ), Liz Ward (CFAHR; UQ), Sanjeewa Kularatna (AushSI QUT); Joshua Byrnes (Griffith University)	Evaluation of two speech pathology service models for swallowing rehabilitation post head and neck cancer treatment	3	n/a
<b>Frances Thomsen</b>	Omar Breik, <b>Susan Laracy, Karina Lewis, Michelle Donovan, Alanna Chatfield (Consumer)</b> .	A retrospective audit of occupational therapy splinting of radial forearm flap donor sites in head and neck cancer	1	n/a
<b>Lauren Rae</b>	<b>Emma Foley</b>	Redesigning occupational therapy cancer-related fatigue education at RBWH		n/a
<b>Sarah Wilson</b>	<b>Clare Burns</b> , Bena Brown (Metro South HHS, UQ)	Development of clinical and videofluoroscopic assessment tools for the evaluation of dysphagia following laryngectomy; An e-Delphi process	4	n/a

## Collaborative Research Activity Involving RBWH Department / Research Group

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited
Anna Edwards (Toowoomba/UQ)	<b>Teresa Brown</b> , Brett Hughes (Cancer Care), Judy Bauer (Monash)	Regional head and neck cancer centre nutrition care and experience	3	72
Elise Gane (PAH)	<b>Shaun O'Leary</b> , Caroline Speksnijder (Uni Medical Centre Utrecht)	Neck rehabilitation after neck dissection for head and neck cancer: a pilot intervention study	3	0
Mikaela Lynch (UQ)	Trevor Russell (UQ), Rachele Pitt (AHPOQ), <b>Leonie Naumann</b>	Essential components of self-management for cancer related lymphoedema: a Delphi study	4	0

Lead Investigator Name (RBWH staff and consumers in bold)	Other Study Investigators (RBWH staff and consumers in bold)	Research Project Title	Consumer involvement	Number of RBWH Patients Recruited
Marissa Ryan (PAH)	Christine Carrington (PAH), Liz Ward CFAHR/UQ), Centaine Snoswell (UQ), <b>Clare Burns</b> , Mhairi Mackinnon (PAH)	Development, implementation, and evaluation of a cancer pharmacy service for adult patients at the Princess Alexandra Hospital	3	n/a
Liz Ward (CFAHR/UQ)	<b>Clare Burns</b> , Laurie Wennerholm (White Plains Hospital New York, UQ)	Examining international laryngectomy care during the COVID-19 pandemic: Informing a consensus-driven pathway for speech language pathology management	3	n/a
Liz Ward (CFAHR/UQ)	Jasmine Jones (UQ), <b>Clare Burns</b> , Laurelie Wall (UQ), Rebecca Nund (UQ), Nicky Graham (QH), Wendy Comben (THHHS), Emily Missenden (NWHHS)	Enhancing speech pathology workforce and service capabilities to deliver services to patients with head and neck cancer	3	n/a
Liz Ward (CFAHR/UQ)	<b>Clare Burns</b> , Kellie Hancock (PAH), Jenny Boxall (PAH), Rachelle Robinson (Prince of Wales Hospital), Molly Barnhart (Prince of Wales Hospital), Penny Stabler (Gold Coast University Hospital)	Changes in pulmonary outcomes of implementing a day and night regimen with heat and moisture exchangers and their adhesives	3	n/a
Laurie Wennerholm (UQ)	<b>Clare Burns</b> , Liz Ward (CFAHR/UQ)	Laryngectomy care pathways: Examining patient and clinician perspectives	3	n/a

## Research Publications

### Authors

Investigator	ORCID ID	Investigator	ORCID ID
Sarah Andersen	<a href="https://orcid.org/0000-0002-9200-8186">https://orcid.org/0000-0002-9200-8186</a>	Elise Treleaven	<a href="https://orcid.org/0000-0002-6982-2593">https://orcid.org/0000-0002-6982-2593</a>
Merrilyn Banks	<a href="https://orcid.org/0000-0003-4467-4608">https://orcid.org/0000-0003-4467-4608</a>	Sarah Wilson	<a href="https://orcid.org/0000-0002-6386-5429">https://orcid.org/0000-0002-6386-5429</a>
Ann-Louise Spurgin	<a href="https://orcid.org/0000-0001-7799-9703">https://orcid.org/0000-0001-7799-9703</a>	Helen MacLaughlin	<a href="https://orcid.org/0000-0001-9617-546x">https://orcid.org/0000-0001-9617-546x</a>
Clare Burns	<a href="https://orcid.org/0000-0002-9752-1739">https://orcid.org/0000-0002-9752-1739</a>	Laura Moroney	<a href="https://orcid.org/0000-0002-4320-907X">https://orcid.org/0000-0002-4320-907X</a>
Joanne Hiatt	<a href="https://orcid.org/0000-0001-7019-6545">https://orcid.org/0000-0001-7019-6545</a>	Teresa Brown	
Belinda Lehn	<a href="https://orcid.org/0000-0001-8635-9417">https://orcid.org/0000-0001-8635-9417</a>	Shaun O'Leary	<a href="https://orcid.org/0000-0002-2574-129X">https://orcid.org/0000-0002-2574-129X</a>
Leonie Naumann			

## Publications in 2024

### Journal Articles (RBWH staff or consumers in bold)

**Brown TE, Byrnes A**, Chan AC, Dwyer K, Edwards A, **Blake CL**, et al. Revalidation of Proactive Gastrostomy Tube Placement Guidelines for Head and Neck Cancer Patients Receiving Helical Intensity-Modulated Radiotherapy. *Current oncology* (Toronto). 2024;31(11):6938-55

**Burns, C.L.**, Hill, A., Ward, E.C., & Kularatna, S. (2024). Integrated speech pathology telepractice service for swallowing rehabilitation: A feasibility study. Poster Session I-24 of the 31st Meeting of the Dysphagia Research Society in 2023, Dysphagia

Cooper C, Gilchrist J, Beatty L, Kirsten L, Sharpe L, Zomerdijs N, **Grier, M**, et al. Development of psycho-oncology telehealth guidelines: a modified Delphi consensus study. *Journal of Psychosocial Oncology Research and Practice* [Internet]. 2024 Jan 1;6(1). Available from: <https://doi.org/10.1097/or9.0000000000000123>

### Journal Articles (RBWH staff or consumers in bold)

Ryan M, Ward EC, **Burns C**, Carrington C, Cuff K, Mackinnon M, et al. Telepharmacy for outpatients with cancer: An implementation evaluation of videoconsults compared to telephone consults using the CFIR 2.0. Exploratory Research in Clinical and Social Pharmacy [Internet]. 2024 Sep 4;16:100501. Available from: <https://doi.org/10.1016/j.rcsop.2024.100501>.

### Book Chapters (RBWH staff or consumers in bold)

**Burns, C.L.**, Hutcheson, K.A., Cunningham, C.L., Ward, E.C. Chapter 20 - Supporting head and neck cancer management: Use of technology in Ward EC, Van As-Brooks CJ. Head and neck cancer: Treatment, Rehabilitation, and Outcomes, Third Edition. Plural Publishing; 2024

**Spurgin, A-L.**, Acton, L.M., **Lehn, B.K.**, Ward, E.C. Chapter 9 - Stoma care and appliances in Ward EC, Van As-Brooks CJ. Head and neck cancer: Treatment, Rehabilitation, and Outcomes, Third Edition. Plural Publishing; 2024

Stone, D., Blyth, K., **Burns, C.**, Howard, G., Ward, E.C. Chapter 8 - Management of the patient with a tracheostomy in Ward EC, Van As-Brooks CJ. Head and neck cancer: Treatment, Rehabilitation, and Outcomes, Third Edition. Plural Publishing; 2024.


## Keynote or Plenary Lectures given in 2024

Date	Title
08/02/24	<b>Burns C.</b> Telehealth models to enhance feeding and swallowing management across the lifespan. UK Swallowing Research Group Conference
29/07/24	<b>Lehn, B.</b> Improving access to shared consumer experiences to support people across their laryngectomy journey. Australian and New Zealand Head and Neck Cancer Society Meeting
	<b>Burns, C.L.</b> , Ward E.C., Russell, T., <b>Spurgin, A.</b> , <b>Currant, M.</b> , <b>Blain, M.</b> , <b>Blotteaux J.</b> Exploring the potential of the HoloLens 2: Enhancing mentored support for specialist speech pathology management via telepractice. Australian and New Zealand Head and Neck Cancer Society Meeting
18/08/24	Dannielle McCormack, Christine Johnson, <b>Teresa Brown, Claire Blake, Rachel Willims, Helen MacLaughlin, Sarah Andersen</b> , Micronutrient requirements post stem cell transplantation and during graft-versus-host-disease: A systematic review, Dietitians Australia 2024
10/09/24	<b>Wilson, S.</b> Clinical and videofluoroscopic evaluation of swallowing following laryngectomy: An international e-Delphi consensus process. MD Anderson Head and Neck Collaborative Webinar.
17/10/24	<b>Burns C.</b> Telepractice in total laryngectomy. 24th National Conference of the Foundation for Head and Neck Oncology India.
13/11/24	<b>Grier M.</b> Raising the bar: Discussions about alcohol after a cancer diagnosis. Invited presentation at the Clinical Oncology Society of Australia Annual Scientific Meeting, Gold Coast, Australia.
14/11/24	<b>Burns, C.L.</b> , Ward E.C., Russell, T., <b>Spurgin, A.</b> , <b>Currant, M.</b> , <b>Blain, M.</b> , <b>Blotteaux J.</b> Exploring the potential of the HoloLens 2: Enhancing mentored support for specialist speech pathology management via telepractice. 2024 Success and Failures in Telehealth Conference.
16/11/24	<b>Andersen, S.</b> Does dietary fibre intake make a difference during cancer treatment? Australian Society of Parental and Enteral Nutrition (AUSPEN)
16/11/24	<b>Andersen, S.</b> Does dietary fibre intake make a difference during cancer treatment? Australian Society of Parental and Enteral Nutrition (AUSPEN)





Belinda Lehn (Speech Pathology) receiving the Consumer Focus Project Award at the RBWH QuARRIES.



Left to right Rachel Willims & Dr Sarah Anderson (Dietetics and Food Services) presenting at the AuSPEN conference.